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 (-)-Deguelin is a natural rotenoid isolated from several botanical sources and has 
attracted much attention from biologists and chemists due to its promising anticancer and 
chemopreventive properties. Recently, we reported that deguelin interfered with ATP 
binding to Heat Shock Protein 90 (Hsp90), a protein associated with the stabilization and 
translocation of hypoxia inducible factor-1α (HIF-1α). First of all, we herein presented the 
enantioselective synthesis of (-)-deguelin accomplished through 12 steps from 
commercially available starting material, 3,4-dimethoxyphenol. The key features of our 
synthesis include the efficient preparation of the precursor for iterative cyclization via 
highly convergent assembly of two aromatic systems and facile construction of the cis-
fused bisbenzopyran skeleton. Construction of the double cyclization precursor involves 
carbonylative epoxide ring opening catalyzed by cobalt and anionic aryl addition of two 
aromatic systems. The cis-fused bisbenzopyran skeleton was achieved by sequential Pd-
catalyzed O- and C-arylation. The Pd-catalyzed O- and C-arylation were greatly improved 
in terms of yield and stereoselectivity compared to previous studies of asymmetric total 
synthesis of (-)-deguelin. 
Another our effort was explanation of SAR for SH-42 and development of novel HIF-1α 
inhibitors targeting the retinal neovascularization disease. Ocular diseases featuring 
pathologic neovascularization are the leading cause of blindness. Anti-VEGF agents have 
been conventionally used for the diseases, however the treatment is reconsidered recently in 
the aspect that VEGF acts as a trophic factor. Accordingly regulating upstream of VEGF, 
such as HIF-1α has emerged as a desirable therapeutic target. We already identified a series 





well as cancer cell. Especially, the potent analog SH-42 exhibited suppressing effects in 
hypoxia-mediated retinal neovascularization and vascular leakage. We herein report a 
complete structure-activity relationship study of ring-truncated deguelin analogs, SH-42 on 
HIF-1α nano-luciferase activity inhibition. The analog SH-199 which contained 2-
fluorobenzene ring in place of 3,4-dimethoxybenzene ring of SH-42 exhibited excellent in 
vitro HIF-1α inhibitory activity with an IC50 of 100 nM. Meanwhile, the analog SH-173 
which has greatly improved water solubility showed significant HIF-1α inhibitory activity 
and anti-angiogenic effect comparable to the analog SH-42. Importantly, as SH-173 which 
has heteroatome-substituted benzene ring replacing the privileged chromene ring 
manifested the equipotent anti-angiogenic inhibitory activity on oxygen-induced 
retinopathy (OIR) model, a structural feature of the analog SH-173 was identified as a 
novel scaffold of HIF-1α inhibitors in lieu of the chromene ring. 
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decarboxylation-alkylation sequence 
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Deguelin (1) is a natural rotenoid isolated from several botanical sources1 and has been 
known as one of the most active natural pesticides and insecticides.2 Deguelin has attracted 
much attention from biologists and chemists due to its promising anticancer and 
chemopreventive properties. It inhibits induction of ornithine decarboxylase, an enzyme 
related with tumor progression.3,4 The fluorescently-labeled deguelin conjugates showed a 
strong cellular co-localization with mitochondria, the site of the electron-transport chain in 
human cells.5  Recently, we reported that deguelin interfered with ATP binding to Heat 
Shock Protein 90 (HSP90), a protein related with stabilization and translocation of hypoxia 
inducible factor-1α (HIF-1α).6-9 In addition, we identified a key skeleton (SH1280 = SH-80, 
2) responsible for HSP90 inhibition and developed a number of pharmacologically and 
toxicologically improved deguelin analogs.10-12 More recently we have disclosed their 
significant suppressing effects in hypoxia-mediated retinal neovascularization and vascular 
























Figure 1. Structures of (-)-deguelin (1), SH1280 (2) and rotenone (3) 
 
1-1. Previous synthetic studies toward racemic deguelin 
According to numerous biological activities and unique structural features, many organic 
chemistry groups have desired achievement of synthesis of key skeleton and total synthesis 





1-2. Previous asymmetric syntheses of (-)-deguelin  
While racemic syntheses of deguelin and a formal synthesis from rotenone were reported 
earlier,11-15 first enantioselective total synthesis of (-)-deguelin was reported in 2010 by 
Winssinger and coworkers.16 In 2013, Scheidt and coworker reported the first catalytic, 
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Scheme 1. Previous reported asymmetric total synthesis of (-)-deguelin 
 
 
In the scheme of asymmetric total synthesis of (-)-deguelin by Winssinger group, 
nucleophilic epoxide opening of vinyloxirane, Heck cyclization, regioselective ring 
cyclization and Wittig reaction afforded chromene containing fragment. Two key fragment 
were condensed by Mitsunobu reaction and ring-closing metathesis afforded the desired 
internal olefin. Diastereomeric ratio in Sharpless asymmetric dihydroxylation with AD mix-
α and yield of completion of total synthesis through 2 steps were only 5 : 1 and 17% 
respectively. 
Recently, Scheidt and coworker reported the first catalytic, enantioselective total synthesis 





as enantiomeric ratio and 25% as key step yield were still low. To conclude, the 
enantioselective synthesis of cis-fused iterative pyran ring formation has been big challenge. 
 On the other hand, our research group previously tried the enantioselective total synthesis 
of (-)-degulelin and established the unified convergent synthetic strategy which has been 















Scheme 2. The synthetic strategy for analogs of deguelin 
  
Our initial synthetic approach to (-)-deguelin is shown in below. We envisioned that 
double Pd-catalyzed arylation of β-hydroxy ketone 5 would give the desired cis-fused 
bisbenzopyran system of 1 through transferring a chirality of the β-hydroxy moiety to the 
α-position of ketone. The final diastereoselective pyran ring formation was anticipated 
based on Pd-catalyzed α-arylation of ketone 4. The first pyran ring formation would be 
possible via Pd-catalyzed O-arylation of β-hydroxy ketone 5, which can be prepared from 
aldehyde 7 via convergent procedure. Anionic addition of chromene 6 to aldehyde 7, which 
is derived by a carbonylative epoxide opening of 8, provides 5. Chromene 6, which was 
reported by us, is conveniently prepared via a sequence of chemoselective propargylation of 
6-nitro-resorcinol, regioselective Claisen rearrangement of the resulting alkylaryl ether, and 


















































Scheme 3. Previous synthetic approach to (-)-deguelin  
 
 Despite extensive research, there were some challenges in our initial paln toward 
asymmetric total synthesis of (-)-deguelin.(Scheme 4) First of all, on account of early stage 
bromination, yield of anionic aryl addition of common intermediate aryl bromide 6 to 
bromoaryl aldehyde which was first key step was not satisfactory. It resulted from side 
reaction of bromoaryl aldehyde with n-butyllithium. In addition, Pd-catalyzed O- and C- 
arylation were also hard to be optimized. Byproduct which was coupled between secondary 
alcohol and arylbromide instead of aryltriflate and low yield were observed in first Pd-
catalyzed O-arylation. The enantiomeric ratio and yield of second Pd-catalyzed C-arylation, 
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1.  A, n-BuLi, THF, -78 oC
2. DMP, NaHCO3, CH2Cl2














Scheme 4. Challenges in previous study 
 
2. Heat Shock Protein 90 and Hypoxia-Inducible Factor-1 alpha 
Heat shock protein 90 (Hsp90) is a protein concerned with maintaining normal folding, 
function and stability of client proteins such as Hypoxia-inducible factor 1 alpha. In normal 





including cell growth, division, differentiation, migration and death.17 Usually, when Hsp90 
plays a role in cellular signaling pathways, dimer of Hsp90 is formed. Hsp90 has two ATP-
binding sites, N-terminal and C-terminal ATP-binding site. The C-terminal domain 
possessing ATP-binding site is responsible for Hsp90 dimerization and contains binding site 
for co-chaperones.18-20 Natural products, geldanamycin and radicicol are known as Hsp90 
inhibitors binding to N-terminal ATP-binging site. While geldanamycin binds towards the 
front of the ATP-binding pocket, radicicol binds at the back of the ATP-binding pocket. The 
molecular machinery in which ATP/TDP binding status dictates the nature of the co-
chaperones or client proteins binding to and released form Hsp90 is called ‘chaperone 
cycle’. In chaperone cycle, ATP-dependent dimerization of the N-terminal domain is crucial. 
Thus, inhibition of ATP binding and hydrolysis gives rise to the recruitment of an ubiquitin 
ligase bring about the proteasomal degradation of client proteins.(Figure 2)21 Owing to this 
well-known structure, function and operating machinery of Hsp90, it has developed over 
the last decade as one of most attractive drug targets for anti-cancer. 22-25 
 
2-1. Hsp90 in cancer 
Hsp90 particularly participates in the development, maintenance and progression of 
tumor.22,23,26 Higher expression level of Hsp90 in cells cause oncogene-transformed and 
malignant condition of cells.27 Many oncogene products or proteins taking part in 
oncogenic process are client proteins of Hsp90. ErbB2, Raf-1 and Akt are client proteins of 
Hsp90 and hallmark trait proteins as self-sufficiency in growth signals. Plk, Wee1 and Myt1 
play a role in hallmark trait as insensitivity to growth suppression signals. PIP and Akt are 
concerned with evasion of apoptosis. Acquisition of limitless replicative potential with 
hTERT is known. Met inducing invasion and metastasis of tumor is also a client protein of 
Hsp90. Importantly, HIF-1, FAK and Akt are responsible for sustained angiogenesis and 







Figure 2. HSP90 domain structure and chaperone cycle  
 
 
2-2. HIF-1α regulation 
Hypoxia-inducible factor 1 alpha (HIF-1α) is one of the most powerful pro-angiogenic 





grow far away from blood vessel. Under the hypoxic condition, tumor has to develop new 
blood vessel to survive. It is known as ‘angiogenesis’ or ‘neovascularization’. HIF-1 which 
upregulates the expression of genes and proteins promoting angiogenesis, anaerobic 
metabolism and other survival cellular signaling pathways is a crucial mediator of the 
hypoxia-response of tumor cells. 
In solid tumor, their rapid expansion rate cause surpassing the vascular supply resulting in 
lacking oxygen delivery. Tumor hypoxic responses are promoted by a variety of hypoxia-
inducible transcription factors including nuclear factor κB (NF-κB), activator protein 1 
(AP-1) and p53. Yet, HIF is the major regulator of hypoxic responses. Particularly, vascular 
endothelial growth factor (VEGF) which is the most potent angiogenic signal protein is 
upregulated by activation of HIF-1 expression.(Figure 3)28-30 
 
 
Figure 3. Tumor hypoxia and expression of HIF-1 
 
Under normal oxygen concentrations called as normoxia, HIF-1α protein undergoes 
hydroxylation with oxygen by Prolyl Hydroxylase Domain (PHD) proteins in the presence 
of Fe2+, 2-oxoglutarate and ascorbate. The von Hippel Lindau protein (VHL) recognizes the 
Hydroxylated HIF-1α and binds to become a complex which is the substrate of the 
recognition module of the E3 ubiquitin ligase complex. This complex induces the 





Subsequently, HIF-1α rapidly degraded via proteolytic degradation of proteasome.31-33 
Another normoxic regulation of HIF activity as a transcriptional factor is commenced with 
hydroxylation of an aspargine residue (Asn803) of HIF sequence. The transcriptional 
activity of this hydroxylated HIF is suppressed by interfering the intheraction with the co-
activators, p300-CBP binding protein complex.34 
In contrast, under oxygen deficient condition, hydroxylation via Proline Hydroxylase is 
limited by low oxygen concentration. Absence of hydroxyl group of HIF-1α proline 
residues(Pro402 and Pro564) prevents VHL from recognizing and binding HIF-1α. This 
molecular signaling pathway results in accumulation of HIF-1α and dimerization with HIF-
1β. Heterodimerization between HIF-1α and HIF-1β is promoted by direct interaction with 
HIF-1α which cause changing and stabilization of HIF-1α conformation. The HIF-1α and 
HIF-1β complex binds to HRE within the promoters of hypoxia-inducible genes and 
recruits p300-CBP binding proteins which are transcriptional co-activators to promote full 






Figure 4. HIF-1α regulation of Hsp90 
 
3. Retinal Neovascularization Disease 
3-1. Disease and therapies 
Angiogenesis on retinal or ocular region causes several ocular diseases called as retinal 
neovascularization disease. Major indications are age-related macular degeneration (AMD), 
diabetic retinopathy (DR), retinopathy of prematurity and central retinal vein occlusion. 
(Figure 5)36 Market size of age-related macular degeneration and diabetic retinopathy is so 
much bigger than the others. The only one therapy is available for these retinal 
neovascularization diseases and that is using anti-VEGF biodrugs which have limitations as 
high-price and genetic toxicity. 






age of 65. Factors of AMD are diverse as genetic and environmental influences including 
hyper-sunlight, oxidative stress, aging, smoking, obesity and hypertension.37 Groups of 
AMD are two, dry and wet macular degeneration.38 The dry-type AMD is defined by the 
presence of non-cellular polymorphous debris, ‘drusen’ between the basal lamina of RPE 
and Bruch’s membrane.39 Leading cause of the blindness is wet AMD although, Only 20% 
of people with AMD have the wet-type.40 The wet-type AMD is defined by the growth of a 
choroidal neovascularization (CNV), which is growth of blood vessels of the 
choriocapillaris grow into the Bruch’s membrane.41 To conclude, vision loss may result 
from CNV formation in ocular regions. 
 
 
Figure 5. Common indications for intraocular anti-VEGF injections 
 
Mechanism of AMD is known as the following sequences starting with hypoxia, chronic 





and decreased circulation in retina cause higher consumption of oxygen, followed by 
hypoxia.44,45 While, thickening of Bruch’s membrane and formation of drusen cause 
stabilization of HIF.71 In addition, it was reported that higher expression of HIF-1α and 
HIF-2α in CNV concerned with AMD.46 
DR occurs in almost every patient exhibiting retinopathy symptoms among the diabetic 
patents. DR is a major reason of the four leading causes of vision loss.47,48  DR is defined 
by biphasic progression with an initial non-proliferative diabetic retinopathy (NPDR) 




Figure 6. Diabetic retinopathy 
 
Since blood glucose concentration gradually increases during the period of initial non-
proliferative stages in diabetic patient, the blood vessels in the retina are weakened. The 
small saccular capillary outpouchings may occur and leak fluid into the retina.50 The fluid 
result in swelling of the macula which cause blurred vision. The resulting hypoxia promotes 
the expression of angiogenic factors followed by neovascularization and make the disease 
into the proliferative stages.51 The neovascular blood vessels in the retina and into the 
vitreous make the vision cloudy.52,53 





an important role in both physiologic and pathologic angiogenesis. Also, the contribution 
on increased permeability across both the blood-retinal and blood-brain barriers has been 
revealed. Based on the preceding results, anti-VEGF agents started to be used in the 
management of ocular diseases. 
The only one therapy is available for these retinal neovascularization diseases and that is 
using anti-VEGF biodrugs which have limitations as high-price and genetic toxicity.  
 
 
Figure 7. Anti-VEGF agents, Lucentis and Avastin 
 
First administration via intravenous injection for wet AMD initiated with Bevacizumab 
(Avastin®) after approval for an off-labeled anti-cancer agent. According to uncontrolled 
open-label clinical studies of Avastin® over 12 weeks and 24 weeks, wet AMD patients 
showed significant improvement in visual function, retinal thickness and angiographic 





from mouse anti-VEGF monoclonal antibody (149 kD) also achieved improvement of the 
wet AMD with minimizing the systemic adverse effects supported by low diffusion rate 
through the retina into the choroid.(Figure 7)54-56 
Modification of the complementary domain region of Avastin®, followed by affinity 
selection produced ranibizumab (Lucents®).57 Lucents® showed the improvement in visual 
outcomes during the phase 3 clinical trial studies and was approved by the FDA for the 
treatment of wet AMD.58,59 While, anti-VEGF agents have been used as treatment of DR 
because VEGF also plays important role in DR with diabetic macular edema. Recently, 
Lucents® is the drug of choice and only FDA-approved medicine for diabetic macular 
edema. 
A number of adverse effects of Avastin® was reported. First, acute intraocular 
inflammation involving sterile endophthalmitis, pseudoendophthalmitis, posterior uveitis 
was reported by the comparison of AMD treatments trial in 2008. In addition, the number 
of patients complaining of systemic adverse effects was higher. On the contrary, both 
adverse effects occurred in lower rate with Lucents®.60-66 The major problem in case of 
Lucents® is higher cost more than $2,000 per a sing dose of administration. It is contrast 
from a single dose of bevacizumab cost, $50. 
Most importantly, neurotoxicity of anti-VEGF condition was well researched and reported. 
VEGF neutralization causes apoptosis of neuroretinal cell and malfunction of retina. Endo 
genous VEGF plays a significant role in development of choriocapillaris, maintaining of 
cone photoreceptor function and regulation of the multiple angiogenesis related genes. 
While direct inhibition of VEGF has been controversial, normal expression level of the 
multiple angiogenesis genes is observed when HIFs are deleted by mutations. Therefore, 
targeting HIFs which are the upstream target of VEGF may maintain physiological 






3-2. Previous studies 
After the development of novel HIF-1α inhibitors based on natural product deguelin, we 
focused on elucidation of structure-activity relationship for representative compounds, SH-
42 and SH-80 discovered as new HIF-1α inhibitors with a novel scaffold, avoiding the 
structural complexity of deguelin.(Figure 8) SH-42 and SH-80 exhibited excellent anti-
proliferative activities in the H1299 cell line and suppressed HIF-1α expression and tested 
significant activity for in vivo model such as mouse choroidal neovascularization (CNV) 
and oxygen-induced retinopathy (OIR) model. The initial synthetic procedure for 
preparation of ring-truncated analogs and chromene ring-truncated analogs has been 
achieved.71,72 
Despite we had synthesized diverse compound derived from representative compounds, 
SH-42 and SH-80, the evaluation and full structure-activity relationship (SAR) for HIF-1α 
inhibition of derivatives have been remaining tasks. It is impossible to select representative 
derivatives of SH-42 or SH-80 before evaluation for anti-angiogenesis and in vivo ocular 
disease model since western blotting of HIF-1α which was primary screening assay is not 
reproducible and has big standard deviations. Thus, we attempt to confirm the activity for 
anti-angiogenesis and in vivo model after completion of full SAR of parent compounds 
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II. Results and Discussion 
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Scheme 5. Previous Pd-catalyzed α-C-arylation 
 
After further attempts for successful cyclization of 4, we decided to replace aryl bromide 4 
with aryl iodide 9, which was anticipated to undergo more facile oxidative addition with 
Pd-catalyst. We ultimately expected that more reactive oxidative addition would result in 
higher conversion yield and lower racemization during the C-arylation. As shown in 
Scheme 6, iodide substitution at the late stage was designed because we concerned that the 
labile aryl iodide moiety would not be tolerable during the O-arylation and preparation of 
the other arylation precursor 10. 
 The most challengeable step in previous enantioselective synthesis of (-)-deguelin is the 
last step, Pd-catalyzed α-C-arylation. Mechanism of α-arylation begins with oxidative 
addition of Pd-ligand complex to arylhalide. In the presence of Pd-aryl complex, α-
metalated ketone undergoes transmetalation toward Pd-aryl-ketone complex generating the 
desired product after reductive elimination of Pd-ligand complex.(Figure 10) The 
epimerization of β–phenoxy group may occur via elimination and oxa-michael addition 
during the presence of the enolether or α-metalated ketone formed from ketone with base 
since already generated (-)-deguelin did not undergo the epimerization in same Pd-






























































α-arylation with activation via enolether
 
Figure 10. proposed mechanism of two type of α-arylation 
 
1-1. Retrosynthetic analysis 
Our synthetic approach to (-)-deguelin is shown in Scheme 6. We envisioned that double 
Pd-catalyzed arylation of β-hydroxy ketone 11 would give the desired cis-fused 
bisbenzopyran system of 1 through transferring a chirality of the β-hydroxy moiety to the 
α-position of ketone. The final diastereoselective pyran ring formation was anticipated 
based on Pd-catalyzed α-arylation of ketone 9. The first pyran ring formation would be 





aldehyde 12 via convergent procedure. Anionic addition of chromene 6 to aldehyde 12, 
which is derived by a carbonylative epoxide opening of 8, provides 11. Chromene 6, which 
was reported by us, is conveniently prepared via a sequence of chemoselective 
propargylation of 6-nitro-resorcinol, regioselective Claisen rearrangement of the resulting 
















































Scheme 6. Retrosynthetic analysis of (-)-deguelin 
 
1-2. Preparation of first Pd-catalyzed cyclization precursor 
As outlined in Scheme 7, the revised synthesis commenced with preparation of the 
advance intermediate 11, which will be iodinated after the first arylation to give the second 

















































1. 6, n-BuLi, THF, -78 oC, 95%
2. TPAP, NMO, 4A MS, 


















Scheme 7. Preparation of first Pd-catalyzed cyclization precursor 
 
Treatment of 3,4-dimethoxyphenol 13 with (S)-glycidyl 3-nitrobenzenesulfonate produced 
epoxide 8 in 98% yield. Carbonylative ring opening of 8 with CO in the presence of 






DIBAL reduction of ester 15 and coupling of the resulting aldehyde with the chromene 
unit 6 followed by DMP oxidation afforded ketone 16. Global deprotection of 16 and 
chemoselective triflation of the resulting diol produced mono-triflate 11 as a first arylation 
precursor. Chemoselective triflation was again extensively examined under a variety 
reaction conditions. Finally, PhN(Tf)2 treatment of diol dissolved by DMF in the presence 
of potassium carbonate provided the desired mono-triflate 11 in 72 % yield, which is higher 
than that for 5. 
 
1-3. First Pd-catalyzed cyclization and late-stage regioselective iodination 
The Pd-catalyzed O-arylation of 11 toward tetrahydropyanone 10 was greatly improved as 
shown in Scheme 8 under the reaction conditions described for aryl bromide 4. At this stage, 
preparation of intermediate 10 by a different strategy and its direct cyclization to (-)-
deguelin was independently reported by Scheidt’s group73 although the conversion yield 
was still not satisfactory. Thus, we executed our own strategy to complete the synthesis of 













1st Pd-catalyzed cyclizationMeO MeO
(S)
11 10  
Scheme 8. Excellent improvement of first Pd-catalyzed cyclization 
 
We exerted our effort for regioselective iodination of 10 without affecting another 
aromatic system, which was coupled before iodination compared to the halogenation 





iodination product 9 in a moderate yield.(Table 1)74-76 The ketone 9 was quantitatively 























Scheme 9. Preparation of second Pd-catalyzed cyclization precursor 
 
Table 1. Optimization of late-stage regioselective iodination 





- MeCN rt 60min Decomposed 
2 AgNO3 MeOH rt O/N





rt O/N 43% 
4 rt 10min 38% 
5 -10℃ 15min 40% 









9 Acetic acid(cat.) 27% 
10 PPTS(cat.) 31% 
11 PTSA(cat.) 34% 
12 TFA(cat.) THF rt 30min 42% 
13 I2(0.3equiv.) 
MeCN rt 60min 
54% 
14 I2(0.6equiv.) 56% 
15 I2(1.1equiv.) 36% 
a Isolation yied of desired monoiodination product, b O/N = over night  
 
 1-4. Endgame of asymmetric total synthesis of (-)-deguelin 
 With the desired silylenol ether 18, we investigated Pd-catalyzed C-arylation to obtain 
the enantiomerically enriched (-)-deguelin (1). Generally, AsPh3 was superior over other 
ligands including P(t-Bu)3 in terms of conversion yield and stereoselectivity. Presumably 





stereoselectivity.77 As shown in Table 2, CsF (1.4 equiv.) as a fluoride source was essential 
to produce the cyclization product. Interestingly, arylation in a co-solvent of toluene and 
THF (10 : 1) with gradual raise of temperature resulted in effective arylation although 
partly racemization was observed in the polar solvent, presumably via initial elimination of 
phenoxy group.73 Noticeably, use of benzene considerably enhanced both enantioselectivity 
and conversion yield. In this particular case, the reaction was completed with minimal 
racemization. Consequently, the final cyclization was completed in 72% conversion yield 
with an 80 : 20 enantiomeric ratio. Reduced time for C-arylation increased 
enantioselectivity up to 90 : 10 although the conversion yield was decreased to 30%. 
Obviously, the significantly improved result is likely due to facile arylation of the iodinated 
precursor as well as optimized reaction conditions including solvent and ligand. 
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toluene O/Na 70 
<10% of 1  







1 (20~40%) 68 : 32 
4 3 3 Degradation  










7 Tol.:THF (10:1) 1 (60%) 45 : 55 
8 m-xylene 1 (23%) 65 : 35 
9 benzene 1 (30%) 90 : 10 
10 benzene 1 (72%) 80 : 20 





a O/N = over night 
 
In summary, total synthesis of (-)-deguelin was achieved through 12 steps with 8.4% 
overall yield. The key feature of our synthesis includes an efficient preparation of the 
double cyclization precursor via highly convergent assembly of two aromatic systems and 
facile construction of the cis-fused bisbenzopyran skeleton via Pd-catalyzed O and C-
arylation. In addition, the key architecture of the intermediate involves carbonylative 
epoxide ring opening catalyzed by cobalt. Our iterative intramolecular arylation strategy 
seems quite widely applicable in the rotenoid synthesis.78 
 
2. Identification and application of representative Hsp90 inhibitor, SH-
42 into cancer 
As we developed the representative ring-truncated analog SH-42, which showed excellent 
inhibitory activity on H1299 cell line and anti-angiogenic effect, the large amount of SH-42 
needed to be synthesized for examinations including cytotoxicity of multiple naïve cell 
lines, mechanism of direct binding to Hsp90, xenograft model derived from patient and 
neurotoxicity which was presented in case of natural product deguelin. 
 
2-1. Large scale synthesis of SH-42 
Previously, we had synthesized the representative analog, SH-42 which was reported as 
SH1242 in 2016, by the reaction sequence starting to anionic coupling between 3,4-
dimethoxyphenylacetaldehyde and bromobenzopyran unit. Yet, bromobenzopyran unit, the 
common intermediate used to synthesis of various 3,4-dimethoxybenzene modified 
derivatives, has limitations of large scale synthesis due to their harsh synthetic reaction 
conditions and unsatisfactory total yield. Thus, we had designed reverse anionic coupling of 





instead of 3,4-dimethoxyphenylacetaldehyde 19 and bromobenzopyran unit, respectively, 
were used. The yield was satisfactory and reaction conditions were much milder. However 
the scale up of SH-42 was successful, the problems were generated such as lots of waste, 

















































Scheme 10. Synthetic history of SH-42 
 
 Finally, we have achieved the efficient synthesis of SH-42 via tandem claisen 
condensation-decarboxylation sequence in one pot reaction.(Scheme 11) From 3,4-
dimethoxyphenylacetic acid 20, the only one step is needed in this green chemistry method 


































NaHMDS, THF, -78°C to -10°C
70 ~ 90% yield
>10 g scale
22 23 21
20 21  
Scheme 11. One step green chemistry method for scale-up of SH-42 
 
2-2. Mechanism study of SH-42 
The C-terminal domain of Hsp90 plays a critical role in dimerization of Hsp90. Despite 
interaction between ATP and the C-terminal domain of Hsp90 was reported, 3D-structure 
and function of the Hsp90 C-terminal domain sequentially possessing a hydrophobic pocket 
has been unknown. The large scale synthesis of SH-42 which is reported as the possible C-
terminal ATP binding inhibitor of Hsp90 has afforded additional investigations to prove the 
biochemical aspects, function and pharmacophore of the Hsp90 C-terminal ATP binding 
site.79-83 
We prepared and used the recombinant Hsp90 proteins including Full Length (FL), N-
terminal (N), middle (M), and C-terminal (C) to perform the equilibrium binding 
examination based on fluorescence. We attempted to assess whether the binding site of SH-
42 are localized within the N- and/or C-terminal domains of Hsp90. In Fgure 11, the 340 
nm fluorescence spectrum which was emitted from each part of Hsp90 with SH-42 excited 
by 258 nm, was shown. The Kd values of SH-42 for the fragmented Hsp90 N- and C-
terminal domains were 27.3 μmol/L and 16.4 μmol/L, respectively. Titration of FL Hsp90 
with SH-42 showed a two-binding curve phase with Kd values of 13.95 μmol/L and 197.1 
μmol/L. Under condition of blocked N-terminal ATP binding site of Hsp90 by 
preincubation with geldanamycin (GAA), the only one binding curve phase with Kd values 






Figure 11. Fluorescence-based analysis of SH-42 and Hsp90 binding 
 
2-3. Applications of SH-42 into cancer 
With the help of large scale synthesis of the representative ring-truncated analog of 
deguelin, SH-42, various expeditions on anti-tumor activities and toxicities have become 
available. 
 
2-3-1. Cytotoxicity of SH-42 for drug-naïve cell lines 
As we concerned the development of the targeted anti-tumor agent toward a second-line 
therapy in the clinical uses, inhibitory activity for colony formation of SH-42 on acquired 
resistant cancer cell lines to anti-tumor drugs such as paclitaxel resistant cancer cell lines 
(H226B/R and H460/R), EGFR TKI gefitinib resistant cancer cell line (PC9/GR), and 
IGF1R TKI linsitinib resistant cancer cell line (H292/R) were assessed. 
 SH-42 decreased the cell viability of the naïve cell lines as well as the drug-resistant cell 
lines. Significant inhibition on anchorage-dependent colony formation of both naïve and 







Figure 12. Inhibitory activity of SH-42 on colony formation of drug resistant cancer cells 
 
2-3-2. Xenograft model for SH-42 
Concerning with adaptation to artificial in vitro assay conditions of cancer cell lines85, we 
examined inhibitory effect of SH-42 on lung cancer growth in Kras-transgenic mice which 
must occur lung cancers with a 100% incidence.86.  SH-42 which had synthesized as 
multi-gram scale afforded the dose of 20 mg/kg that had excellent antitumor activities 
without visible toxicities on NSCLC xenograft model. Intraperitoneal administration with 
the dose of 20 mg/kg SH-42 showed remarkable inhibition of lung cancer progression on 








Figure 13. Anti-tumor formation activity of SH-42 on mutant KRAS-driven Kras transgenic mice 
 
As we assured the clinical utility of SH-42, human NSCLC cell-derived xenograft model 
with SH-42 was performed. First of all, SH-42 reduced the tumor growth on H1299 
xenograft model compared with a control group and also inhibited the tumor growth in case 
of patient-derived xenograft (PDX) model. At the dose of 4 mg/kg via oral gavage 
treatment which is the maximum tolerated dose of deguelin, SH-42 showed significant 




Figure 14. Inhibitory activity of SH-42 on xenograft models 
 
2-3-3. Reduced neuro toxicities induced by SH-42 
In the previous studies and clinical trials, deguelin (1) showed potential toxicities such as 
parkinsonism-like syndrome by decreasing the tyrosine hydroxylase immunoreactivity at 





including neurotoxicity by measurement of tyrosine hydroxylase expression level and body 
weight of rats. Comparison with the effect of SH-42 and deguelin on tyrosine hydroxylase 
immunoreactivity in the substantial nigra in rats manifested that the treatment of deguelin 
decreased the immunoreactivity much more than the treatment of SH-42. This result 
revealed that the potential neurotoxicity is reduced in case of SH-42 compared with 
deguelin. Variation of body weight in rats also showed reduced toxicity of SH-42 compared 
with deguelin. 
On the viability of normal cells and on the neuropathologic lesions in rat brains treated 
with SH-42 were tested. The reduced neuropathologic lesions in rat brains treated with SH-
1242, was determined by immunofluorescence analysis of tyrosine hydroxyase. Body 
weight changes of vehicle- or drug-treated rats were manifested in below.(Con, control; SH, 
SH-1242; Deg, deguelin. *, P < 0.05; **, P < 0.01; ***, P < 0.001, compared with vehicle-
treated control.) (Figure 15)84 
 
Figure 15. Reduced toxicities of SH-42 compared to deguelin 
 
3. Full SAR of novel HIF-1α inhibitors and application of the 
representative analog into retinal neovascularization disease 
Despite therapeutic potential of the ring-truncated deguelin derivatives, structure-activity 
relationship (SAR) studies of the compounds has been limited in terms of structural 





the ring-truncated deguelin derivatives to establish a complete SAR study between the 
derivatives and HIF-1α. First, we analyzed the structure of the compounds SH-42 and SH-
80 into three parts for structural modification.(Figure 16) We investigated a role of 
dimethoxy benzene ring at the A part as introducing diverse substituents on the benzene 
ring. The ketone moiety at the B part was transformed into alcohol, ester and amides. The 
role of substituents at the benzylic position was further studied, following up our earlier 
work.10 C part-modified derivatives were designed on the basis of chromene-truncation 
strategy, which implying the possibility of discovering a novel scaffold for HIF-1α 
inhibition. The synthesized compounds were evaluated by HIF-1α inhibitory activities 
performing luciferase-reporter assay of HRE-A549 cell to establish SAR of the compounds. 
Considering drug-like properties of the compounds as well as results of primary in vitro 
assay, we selected an analog for further biological evaluation. Antiangiogenic activity of the 
selected compound was confirmed by in vitro angiogenesis assays including proliferation 
assay, migration assay, and tube formation assay. Finally, suppressing effect on hypoxia-
mediated retinal neovascularization of the compound was assessed by utilizing the mouse 






























R = H (SH-42)
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Figure 16. Strategy for SAR of SH-42 and SH-80 
 
3-1. Modification of A-part analogs 
The analogs were mostly prepared by linking a benzylic carbon and a carbonyl carbon. The 
synthetic methods of the carbon-carbon bond formation are outlined in Scheme 12. We 
previously reported addition of aryl anion to an aldehyde to afford secondary alcohol which 
was transformed into the corresponding ketone by oxidation reaction.(Scheme 12, Method 
A)10,78 The method is well established, however, the chromene-containing aryl bromide 6 
was prepared by relatively long six steps from resorcinol. To compensate the weak point of 
method A, we also utilized reverse anionic coupling between the phenyl sulfonyl 
intermediates and the chromene-containing aldehyde.(Scheme 12, Method B)89,91 The 
preparation of the chromene unit was simplified into two steps from 2,4-





phenyl sulfonyl moiety. More importantly, both two methods used n-butyllithium to 
generate anion, which need to be optimized or replaced for a large-scale synthesis. We 
successfully established the synthetic method using Claisen-decarboxylation92 to afford 
several A part-modified analogs and the key intermediate for chromene-truncated 








































Scheme 12. Methods of synthesis of A-part modified analogs 
 
Syntheses of the A-part modified analogs through the method A are outlined in Scheme 1. 
Phenethyl alcohols 24 were oxidized to afford the aldehydes. Secondary alcohols 25 were 
prepared by addition of aryl anion generated by treatment of n-butyllithium on aryl bromide 
610 to the aldehydes from 24. Oxidation reactions using Dess-Martin periodinane or 















1. DMP, NaHCO3, CH2Cl2, 0°C to rt
2. 5, n-BuLi, THF, -78°C to rt
DMP, NaHCO3, CH2Cl2, 0°C to rt
24 25
26  
Scheme 13. Synthesis of A-part modified analog via method A 
 
Recently, Wu and coworkers reported Claisen-decarboxylative reaction between carboxylic 
acids and benzoates as a preparative method for aryl ketones.92 The method was preferable 
to two preceding methods in that most phenyl acetic acids were commercially available 
with reasonable prices, whereas phenyl acetaldehyde or phenyl sulfonyl intermediates were 
synthesized through several steps. Furthermore, as already shown in Scheme 14, the 
preparation of the counterpart required only two steps due to electron-withdrawing nature 
of ester moiety. Several A-part modified analogs were synthesized via the method C as 
described in Scheme 14. Phenyl acetic acids were treated with NaHMDS to generate 
dianions, which condensed with methyl benzoate 21 yielded final compounds 28. It is 
noteworthy that dichloro compound 28f was efficiently prepared by the method C (64% 
from phenyl acetic acid 27f and an extra process for methyl benzoate 21 with 65% yield for 
2 steps) compared to the method A (9% from 3,4-dichloridephenethyl alcohol and an extra 










27a R3 = 2-Me
27b R3 = 3-Me
27c R3 = 4-Me
27d R3 = 2-CN
27e R3 = 3-CN
27f R3 = 3,4-di-Cl
OH
O
28a R3 = 2-Me
28b R3 = 3-Me
28c R3 = 4-Me
28d R3 = 2-CN
28e R3 = 3-CN























Scheme 14. Synthesis of A-part modified analogs via method C 
 
We started from A-part modified analogs with diverse substituents. Two methoxy groups 
on A-part was initially thought to be significant moiety as we observed loss of 
antiproliferative activity with demethylated (monohydroxyl or dihydroxyl) deguelin 
analogs. Van Meir and coworkers also reported that dimethoxybezene played a crucial role 
in HIF-1α inhibitory activities of the sulfonamide analogs based on natural product-like 
chemical library.93,94 The SAR of Analog SH-42 is presented in Table 3. The parent 
compound SH-42 with two methoxy groups exhibited HIF-1α inhibitory activity with IC50 
value of 2.15 µM. We first prepared the analogs possessing no subsituent (entry 2) or 
substituent at both of 3- and 4- position (entry 3-6) in line with the analog SH-42. The 
analog in entry 3 which has a dioxolane ring as a tethered form of two dimethoxy 
substituents showed lower activity compared to the analog SH-42, while the analog in 
entry 4 with dioxane ring exhibited enhanced activity. We replaced electron-donating 
methoxy substituent with electron-withdrawing fluorine at 3- and 4- position, as both 
methoxy moiety and fluorine atom were considered to be hydrogen bond acceptors, even 
though there had been controversy over ability of fluorine atom to act as a hydrogen bond 
acceptor.95,96 Difluoro analog in entry 5 showed improved activity to the analog SH-42, 
whereas dichloro analog in entry 6 showed lower activity. Interestingly, analog in entry 2 





nM, which showed the necessity of investigating the role of diverse substituents 
considering hydrogen bond, electronic effect and steric effect deviating from initial SAR 
study of deguelin. As difluoro analog in entry 5 exhibited the enhanced activity, halogen 
atoms were firstly introduced to the benzene ring. Fluoro analogs entry 7-9 and chloro 
analogs entry 10-12 showed same tendency as HIF-1α inhibitory activities were in the 
order of 2- > 3- > 4- position. In addition, fluoro-analogs showed higher activities than 
chloro-analogs in comparison with the same position. The most potent 2-fluoro analog SH-
199 exhibited 20-fold higher activity than the analog SH-42 with an IC50 value of 100 nM. 
Analogs with bigger electron-withdrawing trifluoromethyl group (entry 13-15) and cyanide 
group (entry 16-18) did not show the same tendency as 4-CF3 analog in entry 15 and 4-CN 
analog in entry 18 possessed the most potent activity among the series. Analogs with 
electron-withdrawing group at 4- position showed little change on the activity regardless of 
types of substituents, while analogs at 2- position exhibited decreased activity as the size of 
substituent get bigger, which implies that binding site interacting with 2- position is 
sensitive to the size of substituent. Investigations on role of electron-donating substituents 
started from methoxy group what the analog SH-42 possess. The 3-OMe analog in entry 20 
showed improved activity than the analog SH-42, however methoxy containing analogs in 
entry 19-21 possessed lower activity compared to fluorine (entry 7-9) and chlorine (entry 
10-12) containing analogs with the same position. Phenol analogs 9a – 9c were prepared to 
draw a comparison between methoxy group and hydroxyl group, which could act as a 
hydrogen bond donor. Interestingly, 2-OH analog in entry 22 and 4-OH analog in entry 24 
showed significantly increased activity compared to their methoxy analogs, which 
contradicted the previous SAR study of deguelin using antiproliferative assay.10 Analogs 
containing methyl substituent, which still has electron donating character but no hydrogen 
bond ability showed decreased activity in case the substituent placed at 3- and 4- position 





methyl substituted analogs, and even superior to 2-OH analog in entry 22. Noticeably, 
analogs containing relatively small substituents (F, Cl, OH, Me) at 2-position exhibited 
excellent HIF-1α inhibitory activities with an IC50 of submicromolar level, while analogs 
with substituents over a certain size (CF3, CN, OMe) showed lower activity. This fact 
supported the possibility again that there exists size-limited binding pocket at 2-position of 
benzene ring, without much regard to the electronic character or hydrogen bond ability of 
the substituents. 
 







































7 (SH-199) 2-F 0.10 0.01 
8 3-F 0.36 0.15 
9 4-F 1.02 0.29 
10 2-Cl 0.33 0.07 
11 3-Cl 0.61 0.20 
12 4-Cl 1.27 0.12 
13 2-CF3 2.13 0.75 
14 3-CF3 2.37 0.74 
15 4-CF3 0.60 0.45 
16 (28d) 2-CN 6.33 1.29 
17 (28e) 3-CN 4.59 2.98 
18 4-CN 1.24 0.52 
19 2-OMe 3.21 0.74 
20 3-OMe 0.82 0.20 
21 4-OMe 6.21 2.39 
22 2-OH 0.94 0.41 
23 3-OH 1.44 0.88 
24 4-OH 0.79 0.49 
25 (28a) 2-Me 0.61 0.27 
26 (28b) 3-Me 5.25 2.34 
27 (28c) 4-Me 3.24 3.03 
aData are mean values of three independent experiments. bstandard error. 
 
3-2. Modification of B-part analogs 
We previously synthesized and analyzed the substituent effect on cytotoxicity test at the 
benzylic position of the analog SH-42 that dimethyl substituted analog showed decreased 
antiproliferative activity compared to nonsubstituted analog SH-42 and monomethyl 





fluorine, allyl group and benzyl group at the benzylic position. In accord with previous 
study, bulkier substituents resulted in lower HIF-1α inhibitory activities with the exception 
of methyl substituent (rac-SH-80), which seemed to produce appropriate constraint. We 
prepared the alcohol analog since deguelol, a reduced form of deguelin, exhibited 10-fold 
higher antiproliferative activity than deguelin. We also examined HIF-1α inhibitory activity 
of acetate analog, however both of alcohol and acetate analogs were inferior to the analog 
SH-42. Amide analog with no-substitution group at amide bond was equipotent to the 
ketone analog SH-42 and the analogs with substituted amide showed similar tendency to 
the ketone series in the respect that as the size of alkyl group increased, HIF-1α inhibitory 
activity decreased.(Table 4) 
 
Table 4. Inhibition of HIF-1α nano-luciferase activity by B-part modified analogs 


























































































aData are mean values of three independent experiments. bstandard error.  
 
3-3. Modification of chromene ring-truncated C-part analogs 
A series of chromene-truncated analogs were synthesized via Claisen-decarboxylation as 
shown in Scheme 15. MOM protection on 4-hydroxyl group of methyl 2,4-
dihydroxybenzoate and following methylation gave the methyl benzoate 29. Treatment of 
NaHMDS to a mixture of commercially available 3,4-dimethoxyphenylacetic acid 20 and 
the methyl benzoate 29 at low temperature produced a ketone enolate, which could be 
trapped with iodomethane to give the common intermediate 30. MOM deprotection using 
hydrochloric acid afforded the previously reported phenol intermediate, which could be 
transformed into both oxygen-substituted chromene-truncated analogs and a precursor for 





compounds were synthesized from alkylation of phenol intermediate using iodomethane 
and iodoethane, respectively. Cyclohexyl ether was prepared from Mitsunobu reaction with 
cyclohexanol. While, in order to prepare nitrogen-containing chromene-truncated analogs, 
phenyl triflimide was treated to the phenol intermediate to yield the precursor of Buchwald 
reaction. Final previously reported amine compounds were successfully synthesized from 
palladium-catalyzed Buchwald-Hartwig reaction using palladium acetate as a base and 
corresponding amines. 
The C-part of the analog SH-42 included terminal chromene unit, a key structural feature 
of deguelin. The chromene unit was traditionally known as ‘privileged structure’ with 
versatile binding properties97 and a large number of natural products containing chromene 
unit were reported with a variety of biological activities.98 For this reason, various attempts 
had been made to incorporate chromene unit into therapeutic agents. Nicolaou and 
coworkers constructed natural product-like chemical libraries by the solid-phase synthesis 
of chromene units.99-101 Recently, Van Meir and coworkers investigated on the development 






































































Cs2CO3, toluene, 100 °C
O
One-pot claisen condensation-decarboxylation-alkylation sequence
Common intermediate (30)
20 29
Scheme 15. Preparation of chromene ring-truncated analogs via tandem reaction 
 
We examined the cell growth inhibitory activities of the early deguelin derivatives 
modified on the terminal chromene unit and the result implied that the chromene unit was 
crucial for appropriate interaction with Hsp90. However, the derivatives had two 





modification on the chromene unit to the ring-truncated deguelin analogs. In order to 
establish a complete SAR study of ring-truncated analog SH-42, a series of C-part modified 
analogs were prepared on the basis of chromene-truncation strategy. It also might enable to 
identify a novel scaffold for HIF-1α inhibition which meet novelty requirement escaping 
from well-qualified but not ingenious chromene unit. Especially, truncation of chromene 
ring mediated the introduction of additional polar moiety for improving physicochemical 
properties, which could be beneficial for intravitreal injection, a common administration 
route for ocular diseases.  
The C-part modified analogs possessed methyl substituent at benzylic position since the 
analog rac-SH-80 exhibited slightly higher activity than the analog SH-42. In addition, 
methyl substituent might be advantageous to have conformational rigidity as chromene-
truncated analogs became floppier than chromene containing ones. HIF-1α inhibitory 
activities of the chromene-truncated analogs were presented in Table 5. In the beginning, 
we maintained the methoxy substituent at 2- position to carbonyl moiety as the methoxy 
group in chromene unit was considered to be beneficial in antiproliferative activity. The 
position of oxygen atom (entry 1-4) or nitrogen atom (entry 5-10) was fixed at 4- position, 
following the original position of oxygen in chromene ring. HIF-1α inhibitory activities of 
ether analogs were increased as the size of substituent get bigger. This tendency also 
continued in case of amine analogs, except for the analog containing morpholine substituent, 
which implied that the binding pocket accommodated terminal of the C-part required 
hydrophobic interaction, as shown in previous report.10 Especially, the analog in entry 7, 
SH-173 showed slightly higher activity than the analog SH-42 with IC50 of 2.15 µM, 
suggesting heteroatom-substituted benzene ring as a novel scaffold for HIF-1α inhibitors 
replacing chromene unit. Next, we investigated the importance of methoxy substituent at 2- 
position by comparing analogs in entry 6, 8, 9, 10. And the result showed little differences 












Entry R1 R2 IC50a (µM) S.E.b 
1 
OMe 
OH N.A.c - 
2 OMe N.A. - 
3 OEt 11.68 9.45 
4 OCy 2.59 2.45 
5 N(CH3)2 N.A. - 
6 N(CH2)4 2.82 1.66 
7 (SH-173) N(CH2CH2)2CH2 1.85 0.57 
8 N(CH2CH2)2O 8.74 8.00 
9 
H 
N(CH2)4 2.61 1.27 
10 N(CH2CH2)2O 6.85 2.74 
aData are mean values of three independent experiments. bstandard error. cNo activity (N.A.) indicates that the 
analog exhibit activity with an IC50 higher than 15µM 
 
 
3-4. Kinetic solubility of representative analogs 
Through the SAR study of ring-truncated deguelin analogs, we successfully discovered 
some potent HIF-1α inhibitors with an IC50 of submicromolar level. We also found that the 
analog SH-173, which was modified to possess piperidine substituted benzene ring instead 
of the chromene ring, had higher HIF-1α inhibitory activity than the analog SH-42. With a 
number of possible analogs in hand for additional biological evaluation, we significantly 





proceed further. As previously mentioned, it was due to the common administration route 
for ocular diseases, intravitreal injection. 
 
 
Figure 17. Kinetic solubility of the representative analogs 
 
Kinetic solubility is a one of most popular methods to examine water solubility of drugs. 
High throughput screening for water solubility is possible by this method which directly 
uses DMSO stock solution of bioactive compound to measure water solubility in short 
time.104 We tested the most potent in vitro HIF-1 nano-luciferase inhibitor SH-199 and the 
chromene ring-truncated analog SH-173 compared to SH-42. The solubility of 
representative chromene ring-truncated analog was 93-fold greater than the solubility of 
parent compound SH-42. The result is explained as increasing of polarity by tertiary amine 
moiety and flexibility by truncation of fused ring system, chromene ring. Interestingly, the 
most potent HIF-1 nano-luciferase inhibitor, SH-199 was less water soluble than parent 
compound SH-42 by 3 times. 
 





We examined the effect of the analog SH-173 on hypoxia-mediated angiogenic processes. 
Angiogenesis is a complex process involving extensive interaction between cells, soluble 
factors and extracellular matrix components. The construction of a vascular network needs 
consecutive steps including cell proliferation, migration and tube formation.105 We utilized 
conditioned media (CM) extracted from human colon cancer HCT116 cells treated 
with/without the analog SH-42 and the analog SH-173 under hypoxia. The antiangiogenic 
effects of the compounds were evaluated by observing changes in angiogenic processes 
mentioned above, with the treatment of CM to human umbilical vein endothelial cells 
(HUVECs). The analog SH-173 effectively suppressed hypoxia-induced proliferation, 




Figure 18. Anti-angiogenesis of the chromene ring-truncated analog, SH-173 
 
3-6. Oxygen-inducible retinopathy model for representative analogs 
Followed by in vitro antiangiogenic activity of SH-173, we investigated the efficacy of the 
compound in vivo using the mouse OIR model.8,90 Analogs SH-42 and SH-173 were 
injected intravitreally with two concentrations of 100 nM and 1 µM. Staining of whole-
mounted retinal tissues and its quantitative analysis showed that the analog SH-173 
effectively reduced retinal neovascular tufts at a comparable level to the analog SH-





a novel scaffold replacing chromene ring for the development of novel drugs targeting 
pathological angiogenesis in ocular diseases. 
 
 








In summary, total synthesis of (-)-deguelin was achieved through 12 steps with 8.4% 
overall yield. The key feature of our synthesis includes an efficient preparation of the 
double cyclization precursor via highly convergent assembly of two aromatic systems and 
facile construction of the cis-fused bisbenzopyran skeleton via Pd-catalyzed O and C-
arylation. In addition, the key architecture of the intermediate involves carbonylative 
epoxide ring opening catalyzed by cobalt. Our iterative intramolecular arylation strategy 
seems quite widely applicable in the rotenoid synthesis. In addition, we achieved the most 
efficient large scale synthetic process of the representative deguelin analog, SH-42 and 
explored fine evidences of mechanism of action for Hsp90 inhibition, extensive anti-cancer 
effect and reduced toxicities by using multi-gram scale of SH-42. Moreover, we 
investigated the structural features of the representative B and C ring-truncated deguelin 
analog SH-42 for HIF-1α inhibitory activity using HRE-luciferase reporter assay. We 
established the full SAR on the A-part by introducing benzene rings with diverse 
substituents at various positions instead of 3,4-dimethoxy benzene ring. The analog SH-199, 
which contained 2-fluorobenzene ring instead of 3,4-dimethoxy benzene ring showed the 
great inhibitory effect on HIF-1α nano-luciferase activity with an IC50 of 100 nM. Some of 
simple modifications at benzylic position and the ketone moiety reaffirmed the previously 
reported information regarding proper conformation of ring-truncated deguelin analogs. 
Noticeably, the C-part modified analog SH-173 possessing piperidine substituted benzene 
ring in place of the chromene unit exhibited equipotent HIF-1α nano-luciferase inhibitory 
activity and anti-angiogenic effect in vitro assays compared with SH-42. The SH-173 also 
manifested equipotent inhibitory activity in the OIR model in mice despite the privileged 
chromene ring is absence. These results strongly suggested heteroatom-substituted benzene 










Unless otherwise described, all commercial reagents and solvents were purchased from 
commercial suppliers and used without further purification. Tetrahydrofuran and diethyl 
ether were distilled from sodium benzophenone ketyl. Dichloromethane, triethylamine, 
acetonitrile, and pyridine were freshly distilled with calcium hydride. Flash column 
chromatography was carried out using silica-gel 60 (230-400 mesh, Merck) and preparative 
thin layer chromatography was used with glass-backed silica gel plates (1mm, Merck). Thin 
layer chromatography was performed to monitor reactions. All reactions were performed 
under dry argon atmosphere in flame-dried glassware. Optical rotations were measured 
using a JASCO DIP-1000 digital polarimeter at ambient temperature using 100 nm cells of 
2 mL capacity. Infrared spectra were recorded on a Perkin-Elmer 1710 FT-IR spectrometer. 
Mass spectra were obtained using a VG Trio-2 GC-MS instrument, and high resolution 
mass spectra were obtained using a JEOL JMS-AX 505WA unit. 1H and 13C NMR spectra 
were recorded on either a JEOL JNM-LA 300 (300MHz), JEOL JNM-GCX (400MHz), 
BRUKERAMX-500 (500MHz) or JEOL (600MHz) spectrometers. Chemical shifts are 
provided in parts per million (ppm, δ) downfield from tetramethylsilane (internal standard) 
with coupling constant in hertz (Hz). Multiplicity is indicated by the following 
abbreviations: singlet (s), doublet (d), doublet of doublet (dd), triplet (t), quartet (q), quintet 
(quin) multiplet (m) and broad (br). The purity of the compounds was determined by 
normal phase high performance liquid chromatography (HPLC), (Gilson or Waters, 





1. Chemical Synthesis 








To a solution of (S)-(+)-glycidyl-3-nitrobenzenesulfonate (5.191 g, 19.6 mmol) and phenol 
9 (2.016 g, 13.1 mmol) in dry DMF (39 mL) was added Cs2CO3 (21.528 g, 65.4 mmol) at 
ambient temperature. The reaction mixture was stirred for 4 h and quenched with water, and 
then extracted with EtOAc. The organic layer was washed with 1N NaOH aqueous solution 
and brine, dried over MgSO4, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (EtOAc : n-Hexane = 1 : 3) to afford 
2.806 g (98%) of 8 as a white solid: [α]  +4.4 (c 1.01, CH2Cl2); FT-IR (thin film, neat) νmax 
2955, 2923, 2853, 1598, 1514, 1464 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 6.74 (d, 1H, J = 
8.7 Hz), 6.54 (d, 1H, J = 2.8 Hz), 6.38 (dd, 1H J = 8.7, 2.8 Hz), 4.16 (dd, 1H, J = 11.0, 3.1 
Hz), 3.89 (dd, 1H, J = 11.0, 5.7 Hz), 3.82 (d, 6H, J = 10.9 Hz), 3.32 (m, 1H), 2.87 (t, 1H, J 
= 4.8 Hz), 2.72 (dd, 1H, J = 4.9, 2.6 Hz); 13C-NMR (CDCl3, 125 MHz ) δ 153.1, 149.9, 
143.9, 111.7, 103.9, 101.1, 69.3, 56.4, 55.8, 50.2, 44.6; HR-MS (FAB+) calcd for C11H14O4 














(S)-Methyl 4-(3,4-dimethoxyphenoxy)-3-hydroxybutanoate (14) 
Cobalt carbonyl (2.346 g, 6.2 mmol) was added into a flame-dried 50mL round bottom 
flask. The flask was purged 5 times using CO balloon. Dry methanol (16 mL) was added 
and the mixture was stirred for 2 min. Epoxide 8 (6.490 g, 30.9 mmol) in dry methanol (16 
mL) was added to the previous solution, and CO gas was bubbled into the mixture for 20 
min. The resulting mixture was stirred until complete consumption of the starting material 
(monitored by TLC) at ambient temperature, diluted with ether, and filtered through a pad 
of celite. The filtrate was concentrated under reduced pressure and the residue was purified 
by flash column chromatography on silica gel (EtOAc : n-Hexane = 1 : 3) to afford 6.501 g 
(78%) of (S)-methyl 4-(3,4-dimethoxyphenoxy)-3-hydroxybutanoate 14 as a yellow liquid: 
[α]  -46.8 (c 0.57, CH2Cl2); FT-IR (thin film, neat) νmax 3502, 2998, 2952, 2834, 1736, 
1611, 1597, 1513, 1440 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 6.75 (d, 1H, J = 8.7 Hz), 6.52 
(d, 1H, J = 2.8 Hz), 6.39 (dd, 1H, J = 12.8, 2.8 Hz), 4.38 (m, 1H), 3.94 (d, 2H, J = 5.2 Hz), 
3.83 (d, 6H, J = 10.9 Hz), 3.71 (s, 3H), 3.03 (s, 1H), 2.66 (d, 1H, J = 4.4 Hz), 2.65 (d, 1H, 
J = 7.3 Hz); 13C-NMR (CDCl3, 125 MHz ) δ 172.5, 153.0, 149.9, 143.9, 111.8, 103.9, 100.9, 












Methyl (S)-4-(3,4-dimethoxyphenoxy)-3-(methoxymethoxy)butanoate (15) 





diisopropylethylamine (6.8 mL, 38.6 mmol) at room temperature. The reaction mixture was 
stirred for 5 min and MOM chloride (2.7 mL, 33.2 mmol) was added at 0 °C. The reaction 
mixture was stirred at ambient temperature overnight, quenched with saturated NH4Cl 
solution at 0 °C, and extracted with EtOAc. The organic layer was washed with saturated 
NH4Cl solution and brine, dried over MgSO4, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (EtOAc : n-Hexane 
= 1 : 4) to afford 2.3195 g (96%) of 15 as a yellow liquid: [α]  -4.8 (c 0.87, CH2Cl2); FT-
IR (thin film, neat) νmax 3057, 2994, 2953, 2834, 1737, 1612, 1597, 1512, 1465, 1452, 1439, 
1373 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 6.75 (d, 1H, J = 8.7 Hz), 6.51 (d, 1H, J = 2.7 
Hz), 6.38 (dd, 1H, J = 8.7, 2.7 Hz), 4.74 (m, 2H), 4.33 (m, 1H), 4.00 (dq, 2H, J = 12.8, 4.9 
Hz), 3.82 (d, 6H, J = 11.1 Hz), 3.68 (s, 3H), 3.35 (s, 3H), 2.75-2.66 (m, 2H); 13C-NMR 
(CDCl3, 125 MHz ) δ 171.5, 153.2, 149.9, 143.7, 111.8, 103.8, 100.9, 96.6, 72.8, 69.9, 56.4, 










 (S)-4-(3,4-Dimethoxyphenoxy)-3-(methoxymethoxy)butanal (12) 
To a stirred solution of butanoate 15 (1.2 g, 3.9 mmol) in dry CH2Cl2 (20 mL) was 
dropwise added a solution of DIBAL-H (1.0 M solution in CH2Cl2, 4 mL) in toluene at -
78 °C. The reaction mixture was stirred until complete consumption of starting material 
(monitored by TLC) and Rochelle solution was added dropwise at -78 °C. The reaction 





organic layer was washed with brine, dried over MgSO4, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel (EtOAc : 
n-Hexane = 1 : 3) to afford 1.05 g (96%) of 12 as white solid: [α]  -187 (c 0.82, CH2Cl2); 
FT-IR (thin film, neat) νmax 2998, 2938, 2833, 1725, 1597, 1513, 1452 cm-1; 1H-NMR 
(CDCl3, 500 MHz ) δ 9.83 (s, 1H), 6.74 (d, 1H, J = 8.8 Hz), 6.50 (d, 1H, J = 2.7 Hz), 6.36 
(dd, 1H, J = 2.8, 8.8 Hz), 4.75 (q, 2H, J = 7.0 Hz), 4.45-4.40 (m, 1H), 4.04-3.97 (m, 2H), 
3.83 (s, 3H), 3.81 (s, 3H), 3.36 (s, 3H), 2.83-2.78 (m, 2H); 13C-NMR (C6D6, 100 MHz ) δ 
199.8, 152.7, 149.5, 143.4, 111.6, 103.5, 100.5, 96.0, 70.8, 69.7, 56.0, 55.4, 55.2, 46.0; HR-















To a solution of aryl bromide 6 (1.7 g, 6.4 mmol) in dry THF (20 mL) was added n-BuLi 
(1.6 M solution in hexane, 3.6 mL) at -78 °C The reaction mixture was stirred for 15 min at 
the same temperature and a solution of 12 (1.0 g, 3.6 mmol) in dry THF (20 mL) was added 
at -78 °C. The mixture was stirred for 20 min at -78 °C and then warmed to ambient 
temperature. The resulting mixture was stirred for 5 min, quenched with water, and 
extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, and 
concentrated under reduced pressure. The residue was filtered by short flash column 





diastereomers as a colorless liquid: [α]  -26.6 (c 1.34, CH2Cl2); FT-IR (thin film, neat) νmax 
3504, 2936, 2830, 1599, 1512, 1465, 1370 cm-1; 
To a solution of above product in dry CH2Cl2 (36 mL) was added sodium bicarbonate 
(852mg, 10.1 mmol). Dess-Martin periodinane (2.1 g, 5.1 mmol) was added. After 
complete consumption of secondary alcohol (monitored by TLC) , the reaction mixture was 
quenched with water and extracted with dichloromethane. The organic layer was washed 
with 5% sodium thiosulfate pentahydrate aqueous solution, dried over MgSO4, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (EtOAc : n-Hexane = 1 : 4) to afford 1.5 g (88% for 2steps) of 
16 as a colorless liquid: [α]  -7.8 (c 1.22, CH2Cl2); FT-IR (thin film, neat) νmax 3080, 2969, 
2937, 2830, 1671, 1634, 1590, 1567, 1512, 1463, 1419, 1371, 1315 cm-1; 1H-NMR (CDCl3, 
500 MHz ) δ 7.56 (d, 1H, J = 8.7 Hz), 6.98 (s, 1H), 6.65 (s, 1H), 6.58 (d, 1H, J = 8.0 Hz), 
6.55 (d, 1H, J = 9.3 Hz), 5.66 (d, 1H, J = 4.5 Hz), 4.79 (d, 1H, J = 13.6 Hz), 4.75 (d, 1H, J 
= 13.5 Hz), 4.55 (quint, 1H, J = 10.8 Hz), 4.13 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.78 (s, 
3H), 3.49-3.31 (m, 2H), 3.34 (s, 3H), 1.42 (s, 6H); 13C-NMR (CDCl3, 125 MHz ) δ 197.8, 
158.0, 156.7, 149.4, 149.0, 144.0, 131.0, 130.4, 124.8, 116.5, 116.3, 114.8, 112.7, 101.7, 
100.4, 96.9, 72.7, 72.3, 63.2, 56.6, 56.2, 55.6, 44.7, 27.9; HR-MS (FAB+) calcd for 

















To a solution of 16 (705mg, 1.5 mmol) in dry CH2Cl2 (15 mL) was added boron 
trichloride solution (1.0 M in CH2Cl2, 4.5 mL) at -78 °C. After complete consumption of 
substrate (monitored by TLC), the reaction mixture was quenched with water (15 mL) at -
78 °C and extracted with dichloromethane. The organic layer was washed with brine, dried 
over MgSO4, and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (EtOAc : n-Hexane = 1 : 4) to afford 365 mg (64%) 
of (S)-4-(3,4-dimethoxyphenoxy)-3-hydroxy-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-
yl)butan-1-one 17 as a yellow liquid: [α]  -15.2 (c 0.56, CH2Cl2); FT-IR (thin film, neat) 
νmax 3491, 3087, 2969, 2931, 2837, 1734, 1641, 1614, 1512, 1486, 1463, 1426, 1376 cm-1; 
1H-NMR (CDCl3, 400 MHz ) δ 12.74 (s, 1H), 7.53 (d, 1H, J = 6.6 Hz), 6.75 (d, 1H, J = 6.6 
Hz), 6.68 (d, 1H, J = 7.5 Hz), 6.53 (d, 1H, J = 2.0 Hz), 6.39 (dd, 1H, J = 2.0, 6.5 Hz), 6.31 
(d, 1H, J = 6.7 Hz), 5.56 (d, 1H, J = 7.6 Hz), 4.58-4.54 (m, 1H), 4.00 (d, 1H, J = 3.9 Hz), 
3.83 (s, 3H), 3.81 (s, 3H), 3.24-3.19 (m, 3H), 1.43 (s, 6H); 13C-NMR (CDCl3, 100 MHz ) δ 
203.3, 160.1, 159.8, 153.0, 149.9, 143.8, 131.1, 128.3, 115.6, 113.6, 111.8, 109.3, 108.7, 
103.9, 100.9, 77.9, 71.4, 66.7, 56.4, 55.8, 41.0, 28.3; HR-MS (FAB+) calcd for C23H26O7 


















To a solution of starting alochol 17 (974 mg, 2.4 mmol) in dry DMF (12 mL) were added 
K2CO3 (358 mg, 2.6 mmol) and PhNTf2 (933 mg, 2.6 mmol) at ambient temperature. After 
complete consumption of substrate (monitored by TLC), the reaction mixture was quenched 
with water and extracted with ether. The organic layer was washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (EtOAc : n-Hexane = 1 : 4) to afford 1.141 g (72%) 
of triflate 11 as a yellow liquid: [α]  -11.6 (c 0.97, CH2Cl2); FT-IR (thin film, neat) νmax 
3491, 3080, 2969, 2932, 2835, 1685, 1637, 1602, 1561, 1513, 1465, 1453, 1426, 1370, 
1312 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 7.64 (d, 1H, J = 8.6 Hz), 6.98 (s, 1H), 6.84 (d, 
1H, J = 8.6 Hz), 6.61 (s, 1H), 6.55 (d, 1H, J = 10.1 Hz), 5.84 (d, 1H, J = 10.1 Hz), 4.59 (m, 
1H), 4.09 (dq, 1H, J = 17.0, 4.9 Hz), 3.84 (s, 3H), 3.80 (s, 3H), 3.36-3.23 (m, 2H), 3.17 (d, 
1H, J = 4.5 Hz), 1.45 (d, 6H, J = 2.2 Hz); 13C-NMR (CDCl3, 125 MHz ) δ 198.2, 157.8, 
149.2, 149.1, 144.5, 142.6, 133.5, 130.6, 124.6, 119.7, 116.0, 115.9, 115.8, 114.9, 102.0, 
100.9, 73.4, 66.7, 56.6, 56.2, 43.7, 27.9, 27.9; HR-MS (FAB+) calcd for C24H25F3O9S (M+) 












To triflate 11 (134mg, 0.2 mmol) in dry toluene (2 mL) were added Pd(OAc)2 (8.9 mg, 
0.04 mmol), SPhos (21 mg, 0.05 mmol), and Cs2CO3 (98 mg, 0.3 mmol). The reaction 





temperature and filtered through a pad of celite. The solvent was removed under reduced 
pressure and the residue was purified by flash column chromatography on silica gel 
(EtOAc : n-Hexane = 1 : 4) to afford 79mg (100%) of 10 as a white solid: [α]  -15.5 (c 
0.66, CH2Cl2); FT-IR (thin film, neat) νmax 3070, 2963, 2927, 2856, 1733, 1683, 1637, 1596, 
1578, 1512, 1441, 1393, 1377, 1348, 1321 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 7.70 (d, 1H, 
J = 8.6 Hz), 7.00 (s, 1H), 6.61 (s, 1H), 6.60 (d, 1H, J = 9.6 Hz), 6.47 (d, 1H, J = 8.7 Hz), 
5.56 (d, 1H, J = 10.0 Hz), 4.81 (m, 1H), 4.27 (d, 1H, J = 4.7 Hz), 3.85 (s, 3H), 3.82 (s, 3H), 
2.99 (dd, 1H, J = 16.8, 12.7 Hz), 2.78 (dd, 1H, J = 16.8, 3.2 Hz), 1.44 (d, 6H, J = 16.6 Hz); 
13C-NMR (CDCl3, 150 MHz ) δ 190.1, 159.6, 157.2, 153.0, 150.0 144.1, 128.9, 127.9, 
115.8, 114.7, 111.8, 111.2, 109.3, 104.1, 101.2, 77.5, 76.5, 69.9, 56.4, 55.9, 39.2, 28.4, 













A solution of ketone 10 (46 mg, 0.1 mmol), NIS (29 mg, 0.12 mmol), and TFA (3 μL, 0.04 
mmol) in acetonitrile (12 mL) was stirred for 4 h at ambient temperature. The solvent was 
evaporated reduced pressure and the residue was purified by flash column chromatography 
on silica gel (EtOAc : n-Hexane = 1 : 4) to afford 39 mg (64%) of 9 as a yellow solid: [α]  
-14.6 (c 1.19, CH2Cl2); FT-IR (thin film, neat) νmax 3066, 2959, 2925, 2854, 1734, 1682, 
1637, 1595, 1577, 1504, 1439, 1376, 1347 cm-1; 1H-NMR (CDCl3, 400 MHz ) δ 7.71 (d, 1H, 





5.56 (d, 1H, J = 10.0 Hz), 4.87-4.81 (m, 1H), 4.26 (d, 1H, J = 4.7 Hz), 3.86 (s, 3H), 3.82 (s, 
3H), 3.01 (dd, 1H, J = 12.8, 16.9 Hz), 2.79 (dd, 1H, J = 3.1, 16.9 Hz), 1.45 (s, 3H), 1.41 (s, 
3H); 13C-NMR (CDCl3, 100 MHz ) δ 190.0, 159.6, 157.1, 151.9, 150.2, 145.1, 128.9, 127.9, 
121.5, 115.8, 114.7, 111.2, 109.3, 100.1, 77.5, 76.4, 74.5, 72.0, 56.6, 56.2, 39.3, 28.4, 28.0; 













To a solution of ketone 9 (22 mg, 0.05 mmol) in dry dichloromethane (0.5 mL) were 
added TESOTf (0.02 mL, 0.09 mmol) and triethylamine (0.02 mL, 0.14 mmol) in one 
portion at ambient temperature. The reaction mixture was stirred for 30 min, quenched with 
saturated sodium bicarbonate aqueous solution, and extracted with ethyl aceatate. The 
solvent was removed by reduced pressure and the residue was purified by short flash 
column chromatography on silica gel (EtOAc : n-Hexane/Et3N = 1 : 10 : 0.2) to afford 26 
mg (100%) of 18 as a colorless liquid: [α]  +9.2 (c 0.37, CH2Cl2); FT-IR (thin film, neat) 
νmax 2955, 2934, 2870, 1737, 1630, 1579, 1439, 1359, 1313 cm-1; 1H-NMR (C6D6, 300 
MHz ) δ 7.47 (d, 1H, J = 8.2 Hz), 6.98 (s, 1H), 6.92 (d, 1H, J = 15.0 Hz), 6.66 (d, 1H, J = 
8.2 Hz), 6.32 (s, 1H), 5.34 (m, 1H), 5.24 (d, 1H, J = 10.0 Hz), 4.77 (d, 1H, J = 4.0 Hz), 
4.12 (dd, 1H, J = 10.0, 7.2 Hz), 3.80 (dd, 1H, J = 10.2, 4.3 Hz), 3.24 (s, 3H), 3.22 (s, 3H), 
3.22 (s, 3H), 1.24 (s, 6H), 0.99 (t, 9H, J = 8.2 Hz), 0.70 (q, 6H, J = 8.0 Hz); 13C-NMR 





114.7, 110.4, 109.4, 100.9, 95.1, 76.3, 75.4, 74.6, 72.5, 56.2, 55.6, 30.2, 28.1, 27.9, 6.9, 5.3, 











(-)-Deguelin (1) from Iodosilylenolether (-)-18 
To a mixture of Pd(OAc)2 (1.5 mg, 0.01 mmol), CsF (13.9 mg, 0.09 mmol), and Bu3SnF 
(28 mg, 0.09 mmol), was added As(t-Bu)3 (4.5 mg, 0.015 mmol) in dry toluene (0.15 mL). 
Silylenolether 18 (41.7 mg, 0.07 mmol) in dry benzene (0.50 mL) was added and the 
reaction mixture was stirred at 60°C for 3.5h. The reaction mixture was cooled down to 
ambient temperature and filtered through a pad of celite. The solvent was removed under 
reduced pressure and the residue was purified by flash column chromatography on silica gel 
(EtOAc : n-Hexane = 1 : 4) to afford 19 mg (72%) of 1 as a foaming white solid: [α]  -
25.1 (c 0.15, CH2Cl2); FT-IR (thin film, neat) νmax 2952, 2925, 2853, 1674, 1635, 1598, 
1578, 1513, 1443, 1393, 1378, 1346, 1274, 1235, 1215, 1199, 1148, 1113, 1095, 1079, 1061, 
1011, 910, 893, 818, 771, 735, 704, 679, 635, 609 cm-1; 1H-NMR (CDCl3, 500 MHz ) δ 
7.73 (d, 1H, J = 8.7 Hz), 6.77 (s, 1H), 6.63 (d, 1H, J = 10.1 Hz), 6.43 (d, 1H, J = 8.6 Hz), 
6.43 (s, 1H), 5.54 (d, 1H, J = 10.1 Hz), 4.90 (m, 1H), 4.62 (dd, 1H, J = 3.1, 12.1 Hz), 4.17 
(d, 1H, J = 12.1 Hz), 3.82 (d, 1H, J = 3.1 Hz), 3.79 (s, 3H), 3.75 (s, 3H), 1.43 (s, 3H), 1.35 
(s, 3H); 13C-NMR (CDCl3, 125 MHz ) δ 189.2, 160.1, 156.9, 149.5, 147.4, 143.9, 128.7, 
128.6, 115.8, 112.8, 111.5, 110.4, 109.1, 104.7, 100.9, 77.7, 72.4, 66.3, 56.3, 55.8, 44.4, 





2-2. General procedures 
General Dess-Martin oxidation procedure 
To a solution of alcohol (1 equiv) in CH2Cl2 were added NaHCO3 (3 equiv), Dess-Martin 
periodinane (1.5 equiv) at 0 °C. Then, the reaction mixture was stirred for 1 h at ambient 
temperature and quenched with 10% sodium thiosulfate solution and extracted with CH2Cl2. 
The organic layer was washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel to 
afford the desired product. 
 
General anionic coupling procedure 
To a solution of aryl bromide (1.8 equiv) in THF was added dropwise n-BuLi solution (1.6 
M solution in n-hexane, 1.65 equiv) at -78 °C. The resulting solution was stirred for 30 min 
at -78 °C, and aldehyde (1 equiv) in THF was added. The reaction mixture was stirred for 1 
h at -78 °C. The reaction mixture was washed with saturated NH4Cl solution and extracted 
with EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on silica 
gel to afford the desired product. 
 
General MOM-protection procedure 
To a suspension of sodium hydride (60%, dispersion in paraffin liquid, 1.75 equiv) in 
DMF was added phenol (1 equiv) dissolved in DMF. The reaction mixture was stirred for 
30 min at 0 °C until the evolution of H2 gas ceased. MOMCl (1.6 equiv) was then added at 
0 °C, and the resulting suspension was warmed to ambient temperature and stirred for 2 h. 
The reaction mixture was cooled to 0 °C, diluted with iced water, extracted with Et2O. The 
organic layer was washed with brine, dried over MgSO4, and concentrated under reduced 





the desired product. 
 
General MOM-deprotection procedure 
To a solution of ketone in methanol was added 3N HCl (4 mL / mmol). The resulting 
solution was heated to 60 °C and stirred for 4 h at the same temperature. The reaction 
mixture was cooled to ambient temperature and extracted with EtOAc. The organic layer 
was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel to afford the desired 
product. 
 
General triflation procedure 
To a solution of phenol (1 equiv) in DMF were added potassium carbonate (1.15 equiv) 
and PhNTf2 (1.2 equiv) respectively. The reaction mixture was stirred for 4 h and extracted 
with Et2O. The organic layer was washed with brine, dried over MgSO4, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on silica 
gel to afford the desired product. 
 
General Buchwald-Hartwig reaction procedure 
To a flask charged with palladium acetate (0.1 equiv), BINAP (0.2 equiv) and cesium 
carbonate (1.4 equiv) were added triflate (1 equiv) and amine (1.2 equiv) in toluene and the 
reaction mixture was stirred for 30 min at ambient temperature. The resulting solution was 
heated to 100 °C and stirred overnight at the same temperature. The reaction mixture was 
cooled to ambient temperature, filtered through Celite pad. The residue was purified by 
flash column chromatography on silica gel to afford the desired product. 
 





To a solution of phenol (1 equiv) in acetonitrile were added cesium carbonate (1.5 equiv) 
and alkyl halide (2 equiv) at 0 °C. The resulting solution was stirred for 20 min at 0 °C, and 
warmed up to ambient temperature and stirred for 1 h. The reaction was quenched with 
water, extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel to afford the desired product. 
 
General tandem claisen condensation-decarboxylation procedure 
To a stirred solution of phenyl acetic acid (1 equiv) and benzoate (1.1 equiv) in dry DMF 
(0.02 M) was dropwise added a 1 M solution of NaHMDS (4 equiv) in THF at -10 °C over 
5 min. After completion of the reaction, the solvent was removed by evaporator. The 
residue was extracted with DCM and washed with brine. The extract was concentrated and 
purified by flash column chromatography on silica gel to afford the desired product. 
 
2-3. Large scale synthesis of SH-42 
Methyl 5-hydroxy-2,2-dimethyl-2H-chromene-6-carboxylate (23) 
To a stirred solution of phenol 22 (2.56 g) and 3-methyl-2-butenal (2.97 mL) in absolute 
ethanol were added calcium chloride dehydrate (1.82 g) and trimethylamine (6.9 mL) at 
room temperature. The mixture was warmed to reflux. After completion of reaction, the 
result mixture was cooled down to ambient temperature. The solvent was removed under 
reduced pressure and extracted with ethyl acetate and brine. The extract was concentrated 
and the residue was purified by flash-column chromatography on silica gel (EtOAc : Hex = 
1 : 30) to afford 4.76 (32%) g of 23 1H-NMR (CDCl3, 300 MHz ) δ 7.59 (d, 1H, , J = 8.7 
Hz), 6.69 (d, 1H, J = 9.9 Hz), 6.31 (d, 1H, J = 8.7 Hz), 5.55 (d, 1H, J = 10.0 Hz), 3.88 (s, 






Methyl 5-methoxy-2,2-dimethyl-2H-chromene-6-carboxylate (21) 
Purification by flash column chromatography on silica gel (EtOAc : Hex = 1 : 30) after 
general alkylation protocol of phenol 23 with iodomethane afforded the 108.1 mg (99%) of 
ester 21. 1H-NMR (CDCl3, 300 MHz ) δ 7.66 (d, 1H, , J = 8.6 Hz), 6.62 (d, 1H, J = 10.6 
Hz), 6.56 (d, 1H, J = 8.6 Hz), 5.63 (d, 1H, J = 10.0 Hz), 3.85 (s, 3H), 3.82 (s, 3H), 1.42 (s, 
6H). 
 
Large scale synthesis of SH-42 via tandem reaction 
3,4-Dimethoxyphenylacetic acid with ester 21 afforded the SH-42 as white solid (70 ~ 
90%, multigram scale) purified by recrystallization (purity > 99% determined by HPLC) 
general tandem claisen condensation-decarboxylation procedure. Spectral data were same 
as previous repot.10 
 
2-4. Synthesis of SH-42 and SH-80 analogs 
 1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(2-methoxyphenyl)ethan-1-ol (25) 
 General oxidation procedure using 2-methoxyphenethylalcohol followed by general 
anionic coupling procedure between resulting aldehyde (39.0 mg) and aryl bromide 6 
(104.7 mg) afforded secondary alcohol 25 (77.3 mg, 52% for 2 steps). : 1H-NMR (CDCl3, 
300 MHz ) δ 7.59 (d, 1H, , J = 8.7 Hz), 6.69 (d, 1H, J = 9.9 Hz), 6.31 (d, 1H, J = 8.7 Hz), 




 General oxidation procedure of alcohol 25 (23.0 mg) afforded the 8.6 mg (36%) of final 
26 as pale yellow solid. 1H-NMR (CDCl3, 600 MHz) δ 7.54 (d, J = 8.7 Hz, 1H), 7.22 (dd, J 





Hz, 1H), 6.60 (d, J = 10.1 Hz, 1H), 6.58 (d, J = 8.7 Hz, 1H), 5.65 (d, J = 9.6 Hz, 1H), 4.23 
(s, 2H), 3.81 (s, 3H), 3.74 (s, 3H), 1.43 (s, 6H); 13C-NMR (CDCl3, 150 MHz) δ 198.3, 
157.5, 157.4, 156.3, 131.3, 131.0, 130.4, 128.2, 125.3, 124.4, 120.5, 116.7, 114.8, 112.4, 
110.4, 76.8, 63.1, 55.3, 43.6, 28.0; HR-MS (ESI) calcd for C21H23O4 (M+H+) 339.1591, 
found 339.1580. 
 
1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(o-tolyl)ethan-1-one (28a)  
Secondary alcohol 27a (81.4 mg, 0.54 mmol) afforded 125.5 mg (72%) of 28a as a white 
solid via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:10): 1H-
NMR (CDCl3, 500 MHz) δ 7.52 (d, J = 8.6 Hz, 1H), 7.20 (m, 4H), 6.60 (d, J = 9.8 Hz, 1H), 
6.60 (d, J = 8.7 Hz, 1H), 5.68 (d, J = 10.0 Hz, 1H), 4.27 (s, 2H), 3.79 (s, 3H), 2.23 (s, 3H), 
1.44 (s, 6H); 13C-NMR (CDCl3, 125 MHz) δ 198.0, 157.7, 156.4, 137.0, 134.0, 130.9, 130.5, 
130.2, 127.0, 126.0, 126.0, 125.2, 116.6, 114.8, 112.7, 76.8, 63.2, 46.9, 28.0, 19.8; HR-MS 
(ESI) calcd for C21H23O3 (M+H+) 323.1642, found 323.1648. 
 
1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(m-tolyl)ethan-1-one (28b)  
Secondary alcohol 27b (77.6 mg, 0.52 mmol) afforded 22.1 mg (13%) of 28b as a white 
solid via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:10): 1H-
NMR (CDCl3, 400 MHz) δ 7.49 (d, J = 8.6 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 7.03 (dd, J = 
7.5, 6.8 Hz, 3H), 6.58 (dd, J = 9.7, 8.4 Hz, 2H), 5.66 (d, J = 10.0 Hz, 1H), 4.21 (s, 2H), 
3.74 (s, 3H), 2.30 (s, 3H), 1.43 (s, 6H); 13C-NMR (CDCl3, 100 MHz) δ 198.4, 157.7, 156.4, 
137.9, 134.9, 131.2, 130.5, 130.3, 128.3, 127.4, 126.6, 124.9, 116.5, 114.8, 112.6, 76.8, 






1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-(p-tolyl)ethan-1-one (28c)  
Secondary alcohol 27c (52.1 mg, 0.35 mmol) afforded 70.6 mg (63%) of 28c as a pink 
solid via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:6): 1H-
NMR (CDCl3, 500 MHz) δ 7.48 (d, J = 8.6 Hz, 1H), 7.11 (dd, J = 15.4, 8.1 Hz, 4H), 6.59 
(d, J = 10.3 Hz, 1H), 6.57 (d, J = 8.6 Hz, 1H), 5.66 (d, J = 10.0 Hz, 1H), 4.20 (s, 2H), 3.74 
(s, 3H), 2.29 (s, 3H), 1.43 (s, 6H); 13C-NMR (CDCl3, 125 MHz) δ 198.5, 157.6, 156.4, 
136.1, 131.9, 131.1, 130.4, 129.4, 129.1, 124.9, 116.5, 114.8, 112.6, 76.8, 63.2, 48.2, 28.0, 
21.0; HR-MS (ESI) calcd for C21H23O3 (M+H+) 323.1642, found 323.1649. 
 
2-(2-(2,2-dimethyl-2H-chromen-6-yl)-2-oxoethyl)benzonitrile (28d)  
Secondary alcohol 27d (31.8 mg, 0.20 mmol) afforded 6.6 mg (11%) of 28d as a yellow 
oil via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:4): 1H- 
NMR (CDCl3, 800 MHz) δ 7.77 (dd, J = 7.8, 1.0 Hz, 1H), 7.65 (dd, J = 7.8, 2.2 Hz, 1H), 
7.63 (d, J = 8.6 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 6.68 (d, J = 
10.0 Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 5.87 (d, J = 10.0 Hz, 1H), 4.61 (s, 2H), 3.92 (s, 3H), 
1.43 (s, 6H); 13C-NMR (CDCl3, 200 MHz) δ 195.4, 150.0, 157.8, 140.7, 133.5, 133.2, 132.2, 
131.8, 131.7, 128.2, 125.3, 118.6, 117.2, 115.7, 114.8, 113.4, 77.7, 63.7, 48.1, 28.1; HR-MS 
(ESI) calcd for C20H18NO2 (M+H+) 304.1332, found 304.1349. 
 
3-(2-(2,2-dimethyl-2H-chromen-6-yl)-2-oxoethyl)benzonitrile (28e)  
Secondary alcohol 27e (30.5 mg, 0.19 mmol) afforded 30.1 mg (50%) of 28e as a yellow 
oil via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:4): 1H-





7.47 (d, J = 7.8 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 6.59 (d, J = 9.2 Hz, 1H), 6.57 (d, J = 
10.0 Hz, 1H), 5.68 (d, J = 9.7 Hz, 1H), 4.28 (s, 2H), 3.77 (s, 3H), 1.43 (s, 6H); 13C-NMR 
(CDCl3, 150 MHz) δ 196.6, 158.3, 156.6, 136.6, 134.3, 133.2, 131.1, 130.7, 130.4, 129.0, 
124.1, 118.8, 116.3, 114.8, 112.9, 112.4, 77.0, 63.2, 47.8, 28.0; HR-MS (ESI) calcd for 




Secondary alcohol 27f (18.0 mg, 0.047 mmol) afforded 7.9 mg (45%) of 28f as a yellow 
oil via general tandem claisen condensation-decarboxylation reaction procedure. 
Purification via flash column chromatography on silica gel (EtOAc/n-Hexane = 1:6): 1H-
NMR (CDCl3, 300 MHz) δ 7.49 (d, J = 9.0 Hz, 1H), 7.35 (d, J = 6.9 Hz, 1H), 7.33 (s, 1H), 
7.07 (dd, J = 8.4, 2.4 Hz, 1H), 6.60 – 6.56 (m, 2H), 5.68 (d, J = 9.9 Hz, 1H), 4.19 (s, 2H), 
3.76 (s, 3H), 1.43 (s, 6H); 13C-NMR (CDCl3, 75 MHz) δ 196.9, 158.2, 156.6, 135.3, 132.3, 
131.6, 131.2, 130.8, 130.6, 130.2, 129.1, 124.4, 116.4, 114.8, 112.9, 77.1, 63.3, 47.5, 28.0, 
28.0; HR-MS (FAB) calcd for C20H19Cl2O3 (M+H+) 377.0711, found 377.0709. 
 
methyl 2-methoxy-4-(methoxymethoxy)benzoate (29) 
To stirred solution of phenol 22 (10.24 g, 59.1 mmol) in dry DCM were added DIPEA 
(15.9 mL, 147.7 mmol) and MOMCl (7.16 mL, 88.6 mmol) at 0℃. After completion of 
reaction, the resulting mixture was quenched with water and extracted with DCM. The 
extract was concentrated and purified by flash column chromatography on silicagel 
(EtOAc : Hex = 1 : 15) to afford 13.3 g (100%) of methyl 2-hydroxy-4-
(methoxymethoxy)benzoate. 1H-NMR (CDCl3, 300 MHz ) δ 7.73 (d, 1H, J = 8.9 Hz), 6.60 
(d, 1H, J = 2.4 Hz), 6.51 (dd, 1H, J = 8.9, 2.5 Hz), 5.17 (s, 2H), 3.89 (s, 3H), 3.45 (s, 3H). 





(18.6 mL, 298.0 mmol) afforded 13.4 g (99%) of benzoate 29 via general alkylation 
procedure and flash column chromatography on silica gel (EtOAc : Hex = 1 : 4). 1H-NMR 
(CDCl3, 300 MHz ) δ 7.79 (d, 1H, J = 9.1 Hz), 6.62 – 6.59 (m, 2H), 5.18 (s, 2H), 3.86 (s, 
3H), 3.82 (s, 3H), 3.45 (s, 3H).  
 
2-(3,4-dimethoxyphenyl)-1-(2-methoxy-4-(methoxymethoxy)phenyl)ethan-1-one (30) 
After general tandem claisen condensation-decarboxylation reaction between 3,4-
dimethoxyphenylacetic acid and benzoate 29, the resulting mixture was quenched with 
absolute ethanol (1 mL/1 mmol of NaHMDS) followed by dropwise addition of 
iodomethane (1.1 equiv) at -10℃ and monitored by thin layer chromatography. After 
completion of alkylation sequence, the solvent was removed by reduced pressure and 
dissolved by water followed by extraction with DCM. The organic layer was collected and 
evaporated. Purification of the residue via flash column chromatography on silica gel 
(EtOAc : Hex = 1 : 4) afforded the common intermediate 30 as a colorless oil (70 ~ 90%, 
multigram scale). 1H-NMR (CDCl3, 500 MHz ) δ 7.56 (d, 1H, J = 8.6 Hz), 6.74 – 6.71 (m, 
3H), 6.56 (dd, 1H, J = 8.6, 2.0 Hz), 6.49 (d, 1H, J = 1.9 Hz), 5.14 (s, 2H), 4.67 (q, 1H, J = 
6.9 Hz), 3.82 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.43 (s, 3H), 1.44 (d, 3H, J = 6.9 Hz). 
 
Other intermediates and final compounds 
Other intermediates and final compounds were already synthesized and reported.10,72,106,107 
 
Kinetic Solubility 
Solubility of SH-42, SH-173, and SH-199 was determined in DPBS (Welgene Inc., Daegu, 
Korea). For the determination of equilibrium solubility, the excess amount of each 
compound was dissolved in DPBS, and the mixture agitated for 24 hours in room 





Hamburg, Germany), and filtered with a filter (0.2 μm pore size syringe filter, Minisart 
RC15, Sartorius Stedim Biotech, Goettingen, Germany). The supernatant of the sample was 
diluted with methanol (1:10 dilution for SH-42 and SH-199; 1:100 dilution for SH-173) 
and the mixture analyzed by LC/MS/MS system (Applied Biosystems 3200 Qtrap MS/MS 
system with Alliance Waters e2695 LC system) for their concentration in the media. 
 
 
2. Biological Evaluation 
Binding titration experiments using fluorescence measurements 
To examine the binding properties of SH-42 to Hsp90, fluorescence-based-5-equilibrium 
binding experiments were performed. A full-length protein, truncated N- and Cterminal 
domain of Hsp90 were each equilibrated with various concentrations of ligands before 
measuring fluorescence emission. All titration experiments were conducted at 20°C using a 
Jasco FP 6500 spectrofluorometer (Easton, MD, USA). Ligand stock solutions were titrated 
into a protein sample dissolved in phosphate buffer (pH 7.4) containing 137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4. The total volume of DMSO used to 
solubilize the ligand was less than 2% in all cases. The proteins were excited at 285 nm, 
and the decrease of fluorescence emission at 340 nm after ligand binding was measured as a 
function of ligand concentration. All titration data were fit to a hyperbolic binding equation 
to obtain Kd values. 
 
Cell culture for anti-cancer assay 
HT-22 and RPE cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS) and antibiotics. Other cancer cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS and antibiotics. BEAS-2B and HBE cells were maintained in 





cultured in endothelial cell basal medium [EBM-2 (Lonza Inc., Allendale, NJ, USA)] 
supplemented with EGM-2 SingleQuots (Lonza). HUVECs between passages 3 and 8 were 
used. Cells were incubated at 37°C with 5% CO2 in a humidified atmosphere. Drug-
resistant cells that have acquired resistance to paclitaxel (H226B/R and H460/R) and an 
IGF-1R TKI linsitinib (H292/R) were generated by continuous exposure to increasing 
concentrations of corresponding anticancer drugs for more than 6 months. H226B/K-Ras 
cells were generated by retroviral transduction of mutant K-Ras. 
 
Anchorage-dependent colony formation 
For the anchorage-dependent colony formation assay, cells were seeded onto 6-well plates 
at a density of 300 cells/well and then treated with increasing concentrations of SH-42 for 2 
weeks. The colonies were fixed with 100% methanol, stained with 0.005% crystal violet 
solution at room temperature, and then washed with deionized water 3-5 times. The 
colonies were photographed and counted. SH-42, diluted in complete medium, was added 
to the agar after the top agar solidified. The cells embedded in the top agar were incubated 
for 2 weeks at 37°C with 5% CO2. After incubation, the colonies were stained with MTT 
solution and then photographed and counted. 
 
Animal studies of SH-42 as anti-cancer agent 
All animal procedures were performed according to a protocol approved by the Seoul 
National University Institutional Animal Care and Use Committee (approval numbers 
SNU-121207-2 and SNU-130820-6). For xenograft and PDX experiments, the tumor-
bearing mice were treated with treated with vehicle (10% DMSO in corn oil), SH-42 (4 or 
20 mg/kg), deguelin (4 mg/kg), or geldanamycin (4 mg/kg) by oral gavage (for H292 
xenografts) or intraperitoneal injection (for H1299 xenografts and PDX) six times per week 





administered by intraperitoneal injection (20 mg/kg) once a day for 8 weeks. To examine 
the parkinsonism-like neurotoxic effects of SH-42 and deguelin, 8- to 10-week old 
Sprague–Dawley rats were treated with SH-42 or deguelin (4 mg/kg, dissolved in corn oil) 
by oral gavage every day for 20 days. 
For xenograft experiments, H1299 and H292 cells (5 x 106 cells/mouse) were 
subcutaneously injected into the right flank of 6-week old NOD/SCID or nude mice. For 
patientderived tumor xenograft (PDX) experiments, tumors that had been passed more than 
3 times - 4 - in mice were minced into 2-mm3 pieces and subcutaneously inoculated into 
NOD/SCID mice. After the tumor volume reached 50-150 mm3 , the mice were randomly 
grouped and treated with vehicle and compounds as described in Materials and Methods. 
Tumor growth was determined by measuring the short and long diameters of the tumor with 
a caliper, and body weight was measured twice per week to monitor toxicity. The tumor 
volume was calculated using the following formula: tumor volume (mm3 ) = (short 
diameter)2 × (long diameter) × 0.5. To determine whether SH-42 can inhibit K-Ras-driven 
spontaneous lung tumor formation, the K-Ras (G12D) transgenic mouse model [kindly 
provided by Dr. Guillermina Lozano (MD Anderson Cancer Center, Houston, TX, USA)] 
was used in experiments. To accelerate lung tumor formation, we backcrossed the K-ras 
transgenic mice in a C57BL6/129/sv background into the FVB/N background, which is 
known for its relatively high incidence of spontaneous lung tumors (3). Three-month-old 
mice were randomized into two groups (n=5) and treated with vehicle or SH-42 for 8 
weeks. Tumor growth was monitored using the IVIS-Spectrum microCT and Living Image 
(ver. 4.2) software (PerkinElmer, Alameda, CA, USA). To facilitate tumor monitoring, 
registered axial respiratory-gated CT image analysis and a fluorescence image analyses 
using an MMPSense 680 probe (PerkinElmer; 2 nmol/150 μl in PBS) were performed in 
mice treated with SH-42 or vehicle at 5 months of age as previously described (4,5). The 





vehicle-treated control group. Microscopic evaluations of lung tissue were also performed 
to measure mean tumor number (N) and volume (V) in a blinded fashion after hematoxylin 
and eosin (H&E) staining. The tumor volume was calculated using the following formula: 
V (mm3 ) = (long diameter x short diameter2 )/2, and the tumor load was calculated using 
the following formula: mean tumor number (N) x mean tumor volume (V) in a blind 
fashion. The number and size of tumors were calculated in five sections uniformly 
distributed throughout each lung. 
 
Cell culture and hypoxia treatment for HIF-1α inhibition assays 
Culture conditions for cells were as follows: DMEM (Gibco, Carlsbad, CA) with 10% 
FBS (Gibco) and 1% penicillin-streptomycin (Gibco) for ARPE-19 cells (American Type 
Culture Collection, Manassas, VA); M199 medium (Gibco) with 20% FBS (Gibco), 1% 
penicillinstreptomycin (Gibco), 3 ng/ml bFGF (Millipore, Billerica, MA), and 5 IU/ml 
heparin (Sigma-Aldrich, St. Louis, MO) for human retinal microvascular endothelial cells 
(HRMECs;Applied Cell Biology Research Institute, Kirkland, WA); RPMI1640 (Gibco) 
with 10% FBS (Gibco) and 1% penicillin-streptomycin (Gibco) for SNUOT-Rb1 cells 
(Gibco) with 10% FBS (Gibco), N-2 Supplement (Gibco), and 1% penicillinstreptomycin 
(Gibco) for human brain astrocytes (Applied Cell Biology Research Institute). Cells were 
incubated at 37 °C in an atmosphere of 95% air and 5% CO2. For hypoxia treatment, cells 
were incubated in the hypoxic chamber with 1% O2 (Coy Laboratory, Grass Lake Charter 
Township, MI). 
 
HIF-1α nano-luciferase assay 
HRE-A549 cells stably transfected with hypoxia-response element-luciferase construct 
were incubated in Dulbecco’s modified Eagle’s medium. Following overnight serum 





incubation, the cells were incubated in hypoxia-chamber for 24 h at 37 °C. Luciferase 
activity was measured by adding luciferase assay reagent (Promega, Madison, WI). 
 
Measurement of kinetic water solubility 
Solubility of SH042, SH173, and SH199 (revision required for compound names) was 
determined in DPBS (Welgene Inc., Daegu, Korea). For the determination of equilibrium 
solubility, the excess amount of each compound was dissolved in DPBS, and the mixture 
agitated for 24 hours in room temperature. The mixture was centrifuged at 13,200 rpm for 
10 minutes (Eppendorf 5415R, Hamburg, Germany), and filtered with a filter (0.2 μm pore 
size syringe filter, Minisart RC15, Sartorius Stedim Biotech, Goettingen, Germany). The 
supernatant of the sample was diluted with methanol (1:10 dilution for SH042 and SH199; 
1:100 dilution for SH173) and the mixture analyzed by LC/MS/MS system (Applied 
Biosystems 3200 Qtrap MS/MS system with Alliance Waters e2695 LC system) for their 
concentration in the media. 
 
Preparation of conditioned media (CM) 
H1299 cells were cultured with M199 containing 1% FBS and treated with hypoxia or 
each compound. The media were collected and centrifuged through a centrifugal filter 
device (3 kDa cut-off; Millipore). Because the molecular masses of both compounds (SH-
42 and SH-173) are less than 0.4 kDa and we collected the retentate, this centrifugation was 
regarded as effective to remove any trace of SH-42 and SH-173 from CM 
 
Migration assay 
Migration assay was performed as previously described using Transwell plates (8.0 μm 
pores). The lower wells were filled with fresh M199 (1% FBS) with VEGF or both 





FBS) for the evaluation of hypoxia-mediated migration. HUVECs (1 x 105 cells) were 
loaded on the upper well. After the incubation for 4 hours, the cells were fixed and stained 
with H&E. Migration was quantified by counting the migratory cells using inverted 
phasecontrast microscope (Leica, Wetzlar, Germany). 
 
Proliferation assay 
HUVECs (5 x 103 cells) were seeded in gelatin-coated 96-well plates. After the incubation 
for 24 hours, the media were changed with CM based on M199 (1% FBS) and the cells 
were cultured for additional 24 hours. Cell proliferation was determined by [3H]-thymidine 
incorporation assays as previously described. Labeled DNA was solubilized in 0.2 N 
NaOH/0.1% SDS and quantitatively analyzed by a liquid scintillation counter (Beckman 
Coulter, Brea, CA). 
 
Tube formation assay 
Tube formation was evaluated as previously described. HUVECs (2 x 105 cells) were 
plated on Matrigel (BD, San Jose, CA)-coated 24-well plates in CM based on M199 (1% 
FBS) and incubated for 20 hours. Tube formation was quantitatively analyzed by measuring 
the length of tubes in 5 randomly selected fields (x100 magnification) from each well using 
the Image-Pro Plus (v 4.5; Media Cybernetics, San Diego, CA). 
 
OIR 
Animals : C57BL/6 mice were obtained from Central Lab. Animal (Seoul, Korea). The 
care, use, and treatment of all animals were in agreement with the ARVO statement for the 
use of animals in ophthalmic and vision research and the guidelines established by the 






OIR was induced in newborn mice as previously described.10 Briefly, newborn mice were 
placed in hyperoxia (75 ± 0.5% O2) from postnatal day (P) 7 to P12 and returned to 
normoxia. At P14, we intravitreally injected 1 μl of PBS or each compound (100 nM) into 
the right eyes of mice (n = 6). At P17, the enucleated eyes were processed for further 
analyses. For qualitative analyses, FITC-dextran (500 kDa) was perfused intravenously 1 
hour before the sacrifice. The retinal flatmounts were observed via the fluorescence 
microscope (Olympus, Tokyo, Japan). For quantitative analyses, the eyes were prepared for 
Hematoxylin and eosin (H&E) staining and the slides were observed via the light 
microscope (Carl Zeiss, Oberkochen, Germany). 
 
Statistics. 
Differences between control and treatment groups were assessed using the 2-tailed 
unpaired T-test. All statistical analyses were performed using Prism 5 (GraphPad Software, 
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HPLC Analysis for Iodosilylenolether (18) 
 
















HPLC Analysis for (-)-Deguelin (1) 
 
(-)-Deguelin from (-)-18 (Table 2, entry 3) 








 (-)-Deguelin from (-)-18 (Table 2, entry 7) 








(-)-Deguelin from (-)-18 (Table 2, entry 8) 






(-)-Deguelin from (-)-18 (Table 2, entry 9) 








(-)-Deguelin from (-)-18 (Table 2, entry 10) 








































































































































































































천연물 데구엘린은 예로부터 쓰이던 몇몇 약용식물들에서 분리된 로테노이드 
화합물이다. 데구엘린은 그 구조적 특이성과 강력한 항암 활성 때문에 많은 
학자들에게 주목 받아왔다. HIF-1α를 안정화시키고 세포 핵내로 위치시킨다고 
알려진 Hsp90의 ATP 결합부위에서 ATP의 결합을 방해함으로써 HIF-1α를 
저해한다는 기전을 본 연구실에서 최근 보고한 바 있다. 본 연구에서는 먼저 
상업적으로 구매가능한 3,4-dimethoxyphenol을 출발물질으로 한 12단계에 거친 
천연물 데구엘린의 입체선택적인 전합성을 기술 하였다. 합성의 주요 
특징으로는 두번의 Pd 촉매를 사용한 연속된 cis-융합 형태의 pyran 고리의 합성, 
해당 촉매 반응을 위한 기질의 convergent chemistry를 이용한 효율적인 준비와 
늦은 단계에서의 산촉매 하에 진행하는 선택적인 요오드화 반응을 들 수 있다. 
한편 본 연구에는 천연물 데구엘린의 유도체인 SH-42의 구조-활성관계에 관한 
연구를 통한 망막 신생혈관 질환 치료제의 개발도 기술 하였다. 안구내 
신생혈관 질환은 시력손실 더 나아가 실명을 야기한다. 이러한 질환의 치료제로 
현재 고가의 VEGF를 타겟으로 하는 항체시약이 유일한 치료제로 사용되고 
있는 실정이며 VEGF를 직접 표적으로 하였을 때에 정상 신경 발달등에 
악영향을 끼친다는 연구가 발표되어 새로운 표적의 망막 혈관질환 치료제가 
필요한 실정이다. 따라서 본 연구실에서는 VEGF의 상위 기전인 HIF-1α를 
표적으로 하는 망막혈관질환 치료제를 개발하고자 하였으며 이전 연구로 좋은 
신생혈관 억제 활성의 감소된 독성을 보이는 SH-42를 도출해 낸 바 있다. 
따라서 본 연구는 도출된 SH-42와 SH-80의 구조를 3개의 부분으로 나누어 각 
부분이 바뀐 유도체들을 합성하였고 HIF-1α luciferase reporter assay를 통해 구조-
활성 상관관계를 확립하였다. 그 과정에서 100 nM의 IC50 값을 가지는 강력한 
활성의 HIF-1α 저해제인 SH-199를 도출하였으며 더 나아가 약리활성이 잘 
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알려진 chromene ring을 개열하여 신규성과 개선된 물성을 확보한 SH-173를 
도출하였다. chromene ring이 없는 유도체 SH-173에서도 신생혈관 저해 효과와 
동물 모델에서 평가하였고 각각 SH-42와 유사한 활성을 보인 다는 것을 
확인하였다. 이를 통해 SH-173과 같이, chromene ring이 없는 특징적인 구조를 
갖는 새로운 HIF-1α 저해제의 모핵을 도출하였다. 
주요어 : 입체특이적 전합성, 데구엘린, Pd-catalyzed α-arylation, 저산소유도인자-
1α, 망막혈관질환, 대량합성, 연속된 claisen 축합-탈탄산-알킬화 연계 반응 
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